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VaccinationToxoplasmosis is caused by Toxoplasma gondii, an apicomplexan parasite that is able to infect any nucle-
ated cell in any warm-blooded animal. Toxoplasma gondii infects around 2 billion people and, whilst only
a small percentage of infected people will suffer serious disease, the prevalence of the parasite makes it
one of the most damaging zoonotic diseases in the world. Toxoplasmosis is a disease with multiple man-
ifestations: it can cause a fatal encephalitis in immunosuppressed people; if first contracted during preg-
nancy, it can cause miscarriage or congenital defects in the neonate; and it can cause serious ocular
disease, even in immunocompetent people. The disease has a complex epidemiology, being transmitted
by ingestion of oocysts that are shed in the faeces of definitive feline hosts and contaminate water, soil
and crops, or by consumption of intracellular cysts in undercooked meat from intermediate hosts. In this
review we examine current and future approaches to control toxoplasmosis, which encompass a variety
of measures that target different components of the life cycle of T. gondii. These include: education pro-
grams about the parasite and avoidance of contact with infectious stages; biosecurity and sanitation to
ensure food and water safety; chemo- and immunotherapeutics to control active infections and disease;
prophylactic options to prevent acquisition of infection by livestock and cyst formation in meat; and vac-
cines to prevent shedding of oocysts by definitive feline hosts.
 2020 The Author(s). Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Human toxoplasmosis is a global zoonotic disease with a com-
plex epidemiology and multiple manifestations. It is caused by Tox-
oplasma gondii, a single-celled, eukaryotic parasitic organism
within the supergroup Alveolata, Phylum Apicomplexa, Class Con-
oidasida, Subclass Coccidiasina, Order Eucoccidiorida, Suborder
Eimeriorina and Family Sarcocystidae. Toxoplasma gondii is the
only species in the genus, Toxoplasma, but it is closely related to
Neospora caninum and Hammondia hammondi,with which it shares
morphological, molecular and life cycle traits. A key to understand-
ing the epidemiology and symptomology of toxoplasmosis lies in
an appreciation of the complexity and elegance of its life cycle
(see Ferguson, 2009, for a history and detailed illustrated descrip-
tion); this is also key to control strategies.
Unlike other coccidians, most of which are host-specific,
T. gondii is seemingly able to infect any nucleated cell in anywarm-blooded animal. However, it is only in the intermediate
asexual phase of its life cycle that T. gondii is so promiscuous; in
the sexual phase, only felids can serve as definitive hosts due to
a unique deficiency, amongst mammals, in intestinal delta-6-
saturase activity in cats (Martorelli Di Genova et al., 2019). Addi-
tionally, there is a distinct difference in expression profiles of par-
asite proteins involved in host cell invasion and modulation of
intermediate versus definitive host cells (Behnke et al., 2014;
Hehl et al., 2015); thus, tachyzoites (the rapidly-dividing asexual
stage in intermediate hosts) express a much wider array of pro-
teins that facilitate host cell invasion and modulation of the host
response to infection than do merozoites (the rapidly dividing
asexual stage that is found only in the definitive host intestine),
potentially explaining the capacity of tachyzoites to infect a wide
array of cells.
In intermediate hosts, T. gondii is found within microscopic
cysts in any part of the body but, most especially, in long-lived cells
of the musculature and CNS. Felids become infected when they
ingest these cysts after preying on an intermediate host. During
digestion, the haploid bradyzoite forms of T. gondii are released
from the cysts and invade enterocytes, progressing through
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sive generations of merozoites that reinvade the intestine before
ultimately differentiating into microgametocytes (each able to dif-
ferentiate into 16–30 motile, flagellated microgametes) or
macrogametocytes (each becoming a single sedentary macroga-
mete). The microgametes fertilise the macrogametes, forming a
diploid zygote. Mobilisation of sub-cellular structures – veil- and
wall-forming bodies – within the macrogamete leads to the forma-
tion of a multi-layered wall around the zygote, which is now
referred to as an oocyst. The oocyst wall is extremely resistant to
environmental and chemical insult, enabling the parasite to pass
safely out into the world in the felid host’s faeces. The resilience
of the oocyst wall also provides a haven for meiosis to occur and
complete the sexual reproductive phase of the life cycle (Walker
et al., 2013). This results in the formation of eight haploid, infec-
tious sporozoites, contained within two sporocysts (i.e., four sporo-
zoites per sporocyst), inside an oocyst, which can survive for
months, even years, in soil or water (Freppel et al., 2019).
Herbivorous intermediate hosts, including humans, can become
infected by drinking water, eating fruit or vegetables, or coming
into contact with soil that is contaminated with oocysts of T. gondii.
There is also evidence that the eating of raw or undercooked mar-
ine molluscs can result in infection because oocysts can accumu-
late in these animals after run-off of contaminated soil into
oceans (Freppel et al., 2019; Shapiro et al., 2019). Sporozoites exit
their sporocysts and oocysts during digestion, invade intestinal
cells, transform into tachyzoites (which are also haploid) and dis-
seminate throughout the body. Carnivorous or omnivorous inter-
mediate hosts, again including humans, can also become infected
by eating other infected intermediate hosts. In this case, it is brady-
zoites that are released into the intestine and invade intestinal
cells, differentiate into tachyzoites and disseminate throughout
the body of the host. Tachyzoites reproduce asexually and rapidly,
rupturing and reinvading cells as they do so, until the immune
response of the host drives them into an evasion strategy that sees
them transform back into bradyzoites, which become encased and
protected by a cyst wall inside host cells. A single mature cyst may
contain large numbers of bradyzoites (Ferguson, 2009), and a sin-
gle bradyzoite can establish infection in either an intermediate or
definitive host. Other means by which infection can occur is via
transfer of tachyzoites congenitally (El Bissati et al., 2018) or via
organ transplants (Derouin et al., 2008).
The life cycle of T. gondii underpins its successful dispersal to all
corners of the globe. However, humans have been unwitting con-
tributors to this success. There appear to have been two major
events in the evolution of T. gondii. First, as hypothesised by
Bertranpetit et al. (2017), based on compelling molecular phyloge-
netic data, the most recent common ancestor of present-day
strains of T. gondii appeared ~1.5 million years ago in South Amer-
ica, coincident with an expansion of both potential murine inter-
mediate hosts and potential feline definitive hosts in South
America. This diversification of hosts favoured diversification of
T. gondii too, leading to its spread into North America, via the Isth-
mus of Panama, which formed 2–3 million years ago. From North
America, further spread could occur, across the Bering Strait into
Asia. The second event was far more recent – between 11,000
and 4,000 years ago – that being the genesis of agriculture, in par-
ticular the cultivation of grains in Asia and the Middle East (Shwab
et al., 2018), before further dissemination into Europe, Africa and
Southeast Asia. The adoption of agrarian practices also marked
the start of commensal relationships between humans and house
mice (Mus musculus musculus, Mus musculus domesticus and Mus
musculus castaneus), and between humans and Felis catus, the
house cat, setting in train the rise of the domestic cat and mouse
life cycle for T. gondii. This domestic cycle has since, arguably,
dominated the epidemiology of the parasite in humans and our96livestock, due to the concentrated high levels of oocyst contamina-
tion of farm land that accompanies our commensal relationship
with cats and mice (Shwab et al., 2018). It has, seemingly, even
resulted in the relatively recent introduction of the domestic life
cycle of T. gondii into North America with a concomitant domina-
tion of T. gondii clonal strains in that part of the world (Shwab
et al., 2018).
Today, around 2 billion people are chronically infected with T.
gondii across the world, though seroprevalence rates are particu-
larly high in parts of tropical South America, Southeast Asia and
Africa (Pappas et al., 2009). In an immunocompetent host, T. gondii
infection usually causes mild symptoms only and rarely requires
intervention. This is because the disease-causing tachyzoites are
suppressed quickly by an immune response in which interferon-
gamma (IFN-c) produced by CD4+ T cells plays a central role, sup-
ported by a range of other immune cells, cytokines (including, in
particular, ILs 12, 18, 1 and 2, and tumour necrosis factor), and
innate immune recognition and effector molecules and mecha-
nisms (Sher et al., 2017). However, the consequent differentiation
of tachyzoites into bradyzoites leads to the formation of long-
lived tissue cysts in the muscles and CNS (Montoya and
Liesenfeld, 2004). These possibly persist for the life of the host
(Rougier et al., 2017), also under the control of IFN-c-dependent
processes (Sturge and Yarovinsky, 2014). Tissue cysts are capable
of reactivating into the acute tachyzoite stage and this is of partic-
ular concern for immunocompromised individuals, particularly
AIDS patients, whose CD4+ T cell populations are drastically
reduced. Reactivation can lead to the formation of brain lesions
and associated toxoplasmic encephalitis, which is fatal if left
untreated (Luft and Remington, 1992). A first infection with T. gon-
dii during pregnancy is also of grave concern. It can lead to congen-
ital toxoplasmosis, which may cause miscarriage or stillbirth or
have serious effects for the new-born, which can be life-long and
may include impairment of mental development, hearing or sight
(Weiss and Dubey, 2009). Clinical disease can also occur in other-
wise healthy, immunocompetent adults, in particular manifesting
as ocular toxoplasmosis, one of the most frequently identified
causes of uveitis (Weiss and Dubey, 2009). Infection is also associ-
ated with inflammatory disease (Lidar et al., 2009; Severance et al.,
2012; Shapira et al., 2012), schizophrenia (Torrey et al., 2012), can-
cer and, potentially, several other disorders of the brain (Thomas
et al., 2012; Ngo et al., 2017), although it is often difficult to deter-
mine whether the associations between these diseases and T. gon-
dii infection are causal or correlative. Globally, it is likely that only
a small percentage of people infected with T. gondii ever develop
any manifestations of toxoplasmosis; however, the simple fact that
around 2 billion people are infected by this parasite means that
large numbers of people inevitably suffer significantly. In tropical
South America, severe forms of toxoplasmosis are more prevalent
than in other parts of the world, possibly reflecting the greater
diversity of virulent strains of T. gondii (Bertranpetit et al., 2017;
Shwab et al., 2018) combined with the high occurrence of infection
via ingestion of oocysts (which have undergone recent sexual
recombination and are therefore more genetically diverse than clo-
nal infections derived from bradyzoites) in that part of the world
(Galal et al., 2019). Hence, toxoplasmosis is one of the most dam-
aging zoonotic diseases in the world, causing the loss of 2–8 mil-
lion Disability Adjusted Life Years (Torgerson and Macpherson,
2011).
Despite the combined complexities of the ubiquity of the T. gon-
dii life cycle and the multiple manifestations of human toxoplas-
mosis, control of this disease can potentially be narrowed in
focus to strategies that target and prevent: congenital disease;
reactivation of cysts (especially in immunocompromised people);
formation of tissue cysts in food animals; and, release of oocysts
into the environment. In this review, we present educational, food
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trol human toxoplasmosis, and comment on the prospects for
developing new approaches.2. Public education, food and water safety to control
toxoplasmosis
The governments of many nations, through their health and/or
agricultural departments, issue clear advice and maintain educa-
tional websites explaining how individuals can prevent toxoplas-
mosis. Exemplifying this is the information provided by the
Centers for Disease Control and Prevention, U.S.A. (https://www.
cdc.gov/parasites/toxoplasmosis/prevent.html), which details that,
to avoid toxoplasmosis, people need to:
 feed pet cats canned or dried commercial food only, never raw
or undercooked meat;
 train pet cats to use cat litter;
 change cat litter daily, wearing disposable gloves whilst doing
so;
 keep pet cats indoors, especially at night, to minimise their
hunting activities and outside defecation;
 wear gloves during gardening or any other contact with soil;
 cover sandpits when not in use (as cats prefer sand or loose soil
for defecation);
 wash fruit and vegetables thoroughly before eating;
 not eat undercooked molluscs;
 freeze meat for at least 2 days (at 12 C or lower) before
cooking;
 cook meat to minimum temperatures (e.g., 74 C for poultry,
71 C for minced or ground meat, and 63 C for other cuts of
meat, followed by a minimum 3 min rest period) before eating;
 wash thoroughly any cutting boards, counters, cutlery, crockery
and other kitchen utensils that have been in contact with any
uncooked food of any type;
 wash hands thoroughly after (i) contact with soil or sand, (ii)
food preparation or contact with uncooked food, (iii) contact
with pets or pet faeces (including cat litter), and reinforce with
children the importance of handwashing; and
 avoid drinking untreated water.
Education about toxoplasmosis and how to prevent it is rein-
forced by health professionals, particularly as part of pre- and
neo-natal education and with immunocompromised people. How-
ever, its effectiveness depends on, first, the completeness and accu-
racy of the advice being given and, second, how closely this is
adhered to by patients. There is some doubt about the effectiveness
of educational efforts on toxoplasmosis, with reported variability
in people’s understanding of the existence of the disease and the
risks it poses (Gollub et al., 2008; Pereboom et al., 2013;
Andiappan et al., 2014; Millar et al., 2014; Elsafi et al., 2015;
Chandrasena et al., 2016; Smereka et al., 2018; Velázquez-Hernán
dez et al., 2019) and a lack of rigorous evaluation of programs (Di
Mario et al., 2015). This is, arguably, particularly true in poorer
nations but difficulties in alleviating the burden of, e.g., congenital
toxoplasmosis have also been observed in the U.S.A. (Jones et al.,
2003; Ogunmodede et al., 2005; Montoya and Remington, 2008;
El Bissati et al., 2018). France has been suggested as an exemplar
of success (El Bissati et al., 2018) due to the integration of educa-
tion, mandatory regular screening and diagnosis throughout preg-
nancy, and consequential timely treatment options (described in
depth by McLeod et al., 2014). At the same time, however, the
cost-benefit of screening and diagnosis and the effectiveness of
treatment have been questioned (Opsteegh et al., 2014).
Systematic responses to ensure that food is free from contam-
ination with T. gondii have been proposed (Kijlstra and Jongert,972008; Opsteegh et al., 2014; Alizaddeh et al., 2018). These mea-
sures can be classified as pre- or post-harvest. The former aims
to ensure minimal contamination of farm land or fodder with
oocysts of T. gondii. The latter is aimed at removing or inactivat-
ing cysts or oocysts in or on meat, fruit and vegetables, but is
mainly focused on cysts in meat since oocysts are resistant to
heat, cold and a variety of chemicals. Moreover, washing of fruit
and vegetables by individual consumers is already a widespread
habit and probably reasonably effective at removing oocysts,
assuming clean water is available (Shapiro et al., 2019), though
it should be noted that the increasing availability of pre-
packaged, ‘‘ready to eat” salads is a potential source of infection
(Caradonna et al., 2017). Pre-harvest efforts are, thus, focused
on biosecurity to prevent or restrict the presence of cats and
rodents, and ensure that water for livestock and for irrigation of
crops is clean. This has significant capacity to be successful for
animals raised indoors under controlled husbandry conditions,
the reduction in prevalence of T. gondii cysts in pork with adop-
tion of modern farming techniques being a prime example
(Opsteegh et al., 2014). Such success is, however, less likely for
animals raised on pasture or under free range organic practices.
Programs to ensure neutering of pet cats, combined with effective
programs to reduce the population of stray cats, would poten-
tially help to reduce oocyst contamination of the environment
but would be extremely difficult and costly to initiate and police
(Opsteegh et al., 2014). Vaccination of cats to prevent oocyst
excretion is conceivable, and a live, attenuated vaccine has been
tested on pig farms (Mateus-Pinilla et al., 1999, 2002); the pro-
spects for this approach will be discussed in more detail in Sec-
tion 5. Vaccination of livestock to prevent infection with T.
gondii (discussed in Section 5) or chemoprophylactic prevention
of infection, a la the use of coccidiostats in the treatment of poul-
try coccidiosis (see Chapman et al., 2013), may be conceivable
approaches but the necessarily long-term administration of effec-
tive drugs would be expensive and would also likely cause
unwanted side-effects or even toxicity (Sanchez-Sanchez et al.,
2018). Post-harvest measures involve the inactivation of T. gondii
tissue cysts in meat. This can be achieved through a number of
treatments including freezing, irradiation and high-pressure pro-
cessing (Kijlstra and Jongert, 2008; Opsteegh et al., 2014;
Alizaddeh et al., 2018), but lack of acceptance by consumers
due to significant effects on meat tenderness, texture and per-
ceived quality would likely prove a major impediment to wide-
spread implementation. Opsteegh et al. (2014) have proposed
that selective post-harvest treatment, i.e., targeting only meat
destined to be consumed raw or undercooked, or from known
infected animals or high-risk (i.e., non-biosecure) farms may be
more achievable, whilst acknowledging that the logistics would
not be simple and that screening for confirmed infection would
be costly.
Major outbreaks of toxoplasmosis have been traced to water
contaminated with oocysts for nearly 50 years (Benenson et al.,
1982; Bowie et al., 1997; Bahia-Oliveira et al., 2003; de Moura
et al., 2006; Ferreira et al., 2018; Shapiro et al., 2019). The same
measures listed above to protect individuals and farms from
exposure to oocysts of T. gondii also apply to reducing contamina-
tion of the environment and, therefore, waterways. Detection of T.
gondii oocysts in water relies on a combination of microscopy,
bioassays and molecular techniques but, in general, has lagged
behind development of methods for detecting other water-
borne parasites such as Giardia and Cryptosporidium (Shapiro
et al., 2019). Oocysts are resistant to chemical disinfection proce-
dures generally employed in ensuring sanitary water supplies
(e.g., they are resistant to strong acids, detergents, chlorine,
ozone, ultraviolet radiation) and, therefore, filtration systems
are a necessity (Freppel et al., 2019).
Table 1
Diverse classes of compounds have activity against Toxoplasma gondii in vitro and
in vivo in mouse models of acute and chronic infection. Plus symbol (+) indicates
active, minus symbol () indicates inactive and (ND) is not determined against T.
gondii in the indicated experimental system (either against tachyzoites in vitro, acute









BKI 1294a + + ND
Compound 32b + + +
Compound 24c + + +
Compound 3ad + + +
Electron Transport Chain
Inhibitors
Atovaquonee + + +
ELQ271f + + +
ELQ334 (ELQ316)g + + +
ELQ400h + + ND
Fatty Acid Synthesis
Inhibitors
Triclosani + + +
Folic Acid Synthesis
Inhibitors
JPC-2056 (JPC-2067-B)j + + ND
TRC-19k + ND ND
Compound 3l + + ND
Histone Modification
Inhibitors
FR235222m + ND ND
W363 and W399n + ND ND
Isoprenoid Pathway
Inhibitors
Risedronateo + + ND
Compound 1p + + ND
Atorvastatinq ND + ND
Protein Synthesis
Inhibitors
Clindamycinr + + 
Azithromycins + + 
Guanabenzt + + +
a Doggett et al. (2014), Müller et al. (2017).
b Vidadala et al. (2016).
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Current chemotherapeutic options for toxoplasmosis are lim-
ited (Dunay et al., 2018), notwithstanding a concerted effort in
the last decade to harness high throughput screening strategies
to discover new chemicals, including natural products, with anti-
Toxoplasma activity or to repurpose or improve existing, approved
drugs (Deng et al., 2019). The frontline treatment for toxoplasmo-
sis is a combination of pyrimethamine and sulfadiazine, drugs that
act synergistically by targeting two steps in folic acid metabolism.
Other therapies combine pyrimethamine with clindamycin, azi-
thromycin or atovaquone, or trimethoprim with sulfamethoxazole.
However, all treatments are commonly associated with adverse
side effects and toxicity (Ben-Harari et al., 2017); for example, in
one study, 60% of toxoplasmic encephalitis patients treated with
pyrimethamine and sulfadiazine experienced adverse effects
including hematologic toxicity, rash and fever, which led to 45%
discontinuing therapy (Haverkos, 1987). In immunocompetent
patients with persistent or severe symptoms, pyrimethamine/sul-
fadiazine treatment duration is usually 4–6 weeks. Immunocom-
promised patients require long-term maintenance therapy after
the initial 6 week treatment, since tissue cysts are not eliminated
by any current treatments. The long duration of treatment and
inability to eliminate infection, combined with frequency of side
effects, make current chemotherapeutic options less than ideal
and highlight the need for new anti-Toxoplasma chemotherapeu-
tics. The ideal anti-Toxoplasma agent would have the following
properties:
 decreased toxicity compared with existing drugs;
 safe for use during pregnancy;
 enhanced efficacy compared with existing drugs;
 the ability to target tachyzoites to treat acute infections;
 the ability to target bradyzoites to eliminate tissue cysts; and
 the ability to reach sufficient concentrations in the CNS to elim-
inate parasites in the brain and eye.
In the following sections, we review current and emerging tar-
gets (see also Table 1 and Fig. 1) and challenges of anti-parasitic
chemotherapy for treating human toxoplasmosis.c Rutaganira et al. (2017).
d Janetka et al. (2020).
e Araujo et al. (1991a), Araujo et al. (1991b), Araujo et al. (1992), Romand et al.
(1993), Ferguson et al. (1994), Dunay et al. (2004).
f Doggett et al. (2012).
g Doggett et al. (2012), Doggett et al. (2020), McConnell et al. (2018).
h Doggett et al. (2012), McConnell et al. (2018).
I McLeod et al. (2001), El-Zawawy et al. (2015a, b).
j Mui et al. (2008).
k Welsch et al. (2016).
l Hopper et al. (2019).
m Bougdour et al. (2009), Maubon et al. (2010).
n Maubon et al. (2010).
o Martin et al. (2001), Yardley et al. (2002).
p Ling et al. (2005).
q Li et al. (2013).
r Araujo and Remington (1974).
s Araujo et al. (1991a), Araujo et al. (1991b), Dumas et al. (1994).
t Benmerzouga et al. (2015), Martynowicz et al. (2019), Martynowicz et al.
(2020).3.1. Folic acid metabolism inhibitors
Apicomplexans, like many protozoans, encode a fused dihydro-
folate reductase (DHFR)-thymidylate synthase enzyme that is
important for folate metabolism and nucleotide synthesis
(Ivanetich and Santi, 1990; Trujillo et al., 1996). The frontline treat-
ment for toxoplasmosis, pyrimethamine, targets DHFR by acting as
a folic acid antagonist (Fig. 1). Pyrimethamine acts synergistically
with sulfonamides, which act on dihydropteroate synthase,
another enzyme in the folate synthesis pathway. However, treat-
ment with pyrimethamine and sulfadiazine frequently causes toxic
side effects in patients including hypersensitivity to sulfadiazine
treatment, resulting in skin rashes and fevers (McLeod et al.,
2006), and bone marrow suppression and adverse effects on devel-
oping foetuses caused by folate depletion associated with pyri-
methamine treatment (Serranti et al., 2011). Pyrimethamine is,
therefore, not always recommended for treating congenital infec-
tions during the first trimester of pregnancy.
DHFR-targeting compounds with greater potency against T.
gondii compared with humans have been investigated to overcome
issues associated with pyrimethamine toxicity. For instance,
WR99210 is a T. gondii DHFR inhibitor that is active both in vitro
and in a mouse infection model, and exhibits ~10-fold greater
potency than pyrimethamine (Mui et al., 2005). Further studies
identified theWR99210 analogue, JPC-2067-B, as a potent inhibitor98of tachyzoite proliferation in vitro (50% inhibitory concentration
(IC50) 20 nM), with minimal toxicity against human cells (Mui
et al., 2008). JPC-2067-B can be administered as an orally bioavail-
able prodrug called JPC-2056, which is active in vivo, and exhibits
better pharmacological characteristics than WR99210.
Computational structure-based, rational drug design
approaches have also been utilised to identify compounds with
greater selectivity for T. gondii DHFR over human DHFR. Using
Fig. 1. Summary of some of the targets for chemotherepeutic interventions against Toxoplasma gondii. Targets include processes that occur in the apicoplast, mitochondrion,
and nucleus, as well as the regulation of cytosolic translation and the synthesis of folates and isoprenoids. See Section 3 and Table 1 for further details. Inset depicts the Q
cycle of the mitochondrial electron transport chain (ETC). Electrons (e) derived from mitochondrial metabolism are donated to coenzyme Q (CoQ), then to the Qo site of
Complex III. From here, electrons are transported via cytochrome c (CytC) and Complex IV to O2, or back to CoQ at the Qi site of Complex III. Most inhibitors of the electron
transport chain in these parasites target either the Qi or Qo sites of Complex III. CDPK, calcium-dependent protein kinase; FPPS, farnesyl diphosphate/geranyl geranyl-
diphosphate synthase; IPP, isopentenyl pyrophosphate; MEP, methylerythritol phosphate.
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compound with ~25-fold greater potency against the TgDHFR
enzyme than pyrimethamine (9 nM versus 230 nM IC50) and a
~90-fold greater selectivity for T. gondii DHFR over the human
enzyme (Welsch et al., 2016). A recent structure–activity relation-
ship study further optimised TRC-19 to develop the 2-
methoxypyrimidine, ‘‘Compound 3”, with a resulting IC50 of
1.6 nM against TgDHFR activity, an ~200-fold selectivity for T. gon-
dii DHFR over the human enzyme, and an 50% effective concentra-
tion (EC50) of 13 nM against T. gondii proliferation in an in vitro
culture model (Hopper et al., 2013). In acute T. gondii infection of
mice, treatment with Compound 3 improved survival in a dose-
dependent manner, the highest dose yielding 100% survival over
30 days, as opposed to the vehicle-treated mice, which succumbed
to infection after 6 or 7 days (Hopper et al., 2019). It remains to be
seen whether Compound 3 is effective against chronic infection or
bradyzoite cysts but preliminary pharmacokinetic studies in mice
suggest Compound 3 is able to cross into the CNS (Hopper et al.,
2019). These studies are a promising start in the bid to identify
more selective and potent inhibitors of T. gondii DHFR with the
physicochemical characteristics needed to avoid the toxicity asso-
ciated with current pyrimethamine and sulfadiazine treatment.3.2. Mitochondrial electron transport chain inhibitors
The mitochondrial electron transport chain consists of a series
of protein complexes embedded in the inner mitochondrial mem-
brane and plays a key role in pyrimidine biosynthesis and oxidative99phosphorylation, a process by which T. gondii parasites can gener-
ate adenosine triphosphate (ATP) (Hayward and van Dooren,
2019). Several enzymatic reactions that take place in the mito-
chondrion (e.g., reactions in the tricarboxylic acid cycle) result in
the transfer of electrons to coenzyme Q (CoQ), an electron carrier
embedded in the inner mitochondrial membrane (Fig. 1, inset).
Complex III (also known as the cytochrome bc1 complex) facilitates
the net transfer of electrons from CoQ to cytochrome c, a mobile
electron carrier in the mitochondrial intermembrane space
(Fig. 1, inset). Electrons from cytochrome c are transferred to Com-
plex IV of the electron transport chain, where they ultimately
reduce O2 (Fig. 1, inset). Electron transport through Complexes III
and IV is coupled to the translocation of protons across the inner
mitochondrial membrane, generating a proton gradient that can
be utilised by ATP synthase (Complex V) for the synthesis of ATP.
The cytochrome b protein of Complex III interacts with CoQ in a
process known as the ‘‘Q-cycle” (Fig. 1, inset). Reduced CoQ docks
at the so-called Qo site of cytochrome b, donating electrons to
either the iron-sulfur cluster of the Rieske protein of Complex III
(from where it is transported onward through the remainder of
the electron transport chain), or to a second CoQ docking site on
cytochrome b called the Qi site (Fig. 1, inset). At the Qi site, oxidised
CoQ is reduced, removing protons from the mitochondrial matrix
and thereby contributing to the proton gradient across the inner
membrane.
The Qo and Qi sites of cytochrome b are targets of a broad range
of anti-parasitic drugs, including compounds that target T. gondii
(Fig. 1, inset). The best studied of these is atovaquone, which tar-
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et al., 1993; McFadden et al., 2000). Early studies showed that ato-
vaquone has activity against tachyzoites and tissue cysts both
in vitro and in vivo (Araujo et al., 1991a, 1991b, 1992; Romand
et al., 1993; Ferguson et al., 1994; Dunay et al., 2004). However,
clinical trials have had mixed results regarding the ability of ato-
vaquone to prevent relapse of infection, with between 12 and
26% of patients experiencing relapse after 1 year, and up to 75%
after 6 years of therapy (Katlama et al., 1996; Pearson et al.,
1999). Instances of failure of atovaquone treatment have also been
reported (Baatz et al., 2006; Megged et al., 2008). These studies
suggest that atovaquone does not completely eliminate tissue
cysts in humans. Given that many clinical trials were retrospective,
non-randomized and non-comparative, more clinical data is
required to evaluate the true efficacy of atovaquone, ideally com-
paring the rates of relapse in patients given atovaquone or pyri-
methamine and sulfadiazine, or combinations of these treatments.
There has been much interest in developing Complex III inhibi-
tors with better potency and bioavailability than atovaquone. The
endochin-like-quinolone (ELQ) series of 4(1H)-quinolone-3-
diarylethers can target the Qi site and/or the Qo site depending
on their chemistry. The Qi site inhibitors ELQ-271 and ELQ-316
are potent inhibitors of T. gondii proliferation in vitro (IC50 values
of 0.1 and 0.007 nM, respectively) and in treating acute infection
in mice, with a high selectivity in targeting the T. gondii complex
over the human Complex III (>90,000-fold and >106-fold, respec-
tively) (Doggett et al., 2012). Notably, ELQ-271 and ELQ-316 treat-
ment reduced T. gondii brain cysts by up to 88% in mice (Doggett
et al., 2012), suggesting these compounds are active against both
tachyzoites and bradyzoites in vivo. ELQ-400 targets both the Qo
and Qi sites of cytochrome b, and exhibits greater efficacy in treat-
ing acute T. gondii infections in mice than both atovaquone and
ELQ-316 (McConnell et al., 2018; Song et al., 2018).
The aforementioned ELQs exhibit low aqueous solubility and
high crystallinity, which may limit their oral bioavailability. A car-
bonate ester prodrug of ELQ-316, called ELQ-334, was created and
shown to both improve bioavailability and prolong the survival of
mice in an acute infection model (Doggett et al., 2020). Oral treat-
ment with ELQ-334 also reduced the brain cyst burden by up to
83% in mice chronically infected with T. gondii parasites (Doggett
et al., 2020). While smaller than non-treated cysts, the tissue cysts
that survived ELQ-334 treatment were viable and capable of estab-
lishing an infection in naïve mice (Doggett et al., 2020), suggesting
that ELQ-334 treatment does not entirely clear brain cysts.
Mutations in the Qo and Qi sites of cytochrome b are common
causes of resistance against compounds that target these sites
(McFadden et al., 2000; Alday et al., 2017). The potential of inhibi-
tors that target both the Qo and Qi site, such as ELQ-400, or combi-
nation therapy with Qo and Qi site inhibitors as dual Complex III
inhibitors, could slow the emergence of drug resistance and
thereby provide more effective treatments against tissue cysts.
While yet to be tested in T. gondii infection, a combination of
ELQ-334 (Qi site inhibitor) and atovaquone (Qo site inhibitor)
cleared mice of infection with Babesia microti, a related apicom-
plexan parasite, with no recrudescence after 122 days (Lawres
et al., 2016).
3.3. Calcium-dependent protein kinase-1 inhibitors
Calcium-dependent protein kinases (CDPKs) are a family of ser-
ine/threonine protein kinases found in plants and numerous proto-
zoans, including apicomplexans (Billker et al., 2009). The T. gondii
genome encodes 14 CDPKs, and these are predicted to function
in a range of calcium signaling-dependent processes across the life
cycle of the parasite (Long et al., 2016). TgCDPK1 is important for
tachyzoite proliferation, where it functions in calcium-dependent100microneme secretion, a process that is critical for parasite egress
from host cells, gliding motility and invasion of parasites into
new host cells (Lourido et al., 2010). TgCDPK1 can be effectively
inhibited by so-called bumped kinase inhibitors (BKIs; Fig. 1),
which are considered to be promising potential therapies against
apicomplexan parasites (Choi et al., 2020). BKIs target the ATP
binding pocket of TgCDPK1, and the selectivity of BKIs for TgCDPK1
over host kinases (and other CDPKs encoded by T. gondii) lies in the
presence of a small ‘‘gatekeeper residue” (a glycine) in the ATP
binding site of TgCDPK1, as opposed to bulkier residues such as
methionine found in human kinases. Several BKI scaffolds have
been identified, with pyrazolopyrimidines (PPs) and 5-
aminopyrazole-4-carboxamides (ACs) the two main classes. The
structure of TgCDPK1 has shown that BKIs act as competitive inhi-
bitors in the ATP binding pocket (Ojo et al., 2010), which has facil-
itated several structure-based drug development programs
(Cardew et al., 2018) that have led to improved pharmacology, effi-
cacy and safety of BKIs (Choi et al., 2020).
The PP compound, BKI 1294, had an in vitro IC50 of 140 nM and
showed efficacy against acute infection in mice when administered
orally (Doggett et al., 2014). Oral administration of BKI 1294 also
increased the survival of pups from 31% to 100% in a congenital
infection of mice, with only 7% of pups positive for brain infection
(Müller et al., 2017). However, a potential for cardiotoxicity via
inhibition of the ion channel human Ether-a-go-go-Related Gene
(hERG) was discovered and prevented progression of this com-
pound into clinical development (Ojo et al., 2014). To overcome
this, a line of optimized PP-based BKIs were developed to avoid
hERG inhibition (Vidadala et al., 2016). ‘‘Compound 32” from this
study had an in vitro IC50 of 60 nM and, importantly, was able to
cross into the CNS and reduce the number of brain cysts by 88%
in a chronic infection of mice (Vidadala et al., 2016). Another struc-
ture–activity relationship study into PP molecules identified a
compound (‘‘Compound 24”) that reduced dissemination of para-
sites from the peritoneal cavity to the brain in acute infection of
mice (Rutaganira et al., 2017). Compound 24 also reduced brain
cyst burden and cured 40% of mice or delayed death in 60% of mice
in a reactivation model of parasite infection in immunocompro-
mised mice (Rutaganira et al., 2017).
Structure-activity relationship studies have also progressed the
development of BKIs with an AC scaffold (Zhang et al., 2014). In one
study, structural optimisation of compounds with an AC scaffold
led to the production of ‘‘Compound 35”, a molecule that is able
to cross into the CNS with a lower in vitro IC50 (89 nM) and
improved pharmacokinetic properties compared with the starting
compound (Huang et al., 2015). The development of improved BKIs
via the incorporation of AC and PP scaffolds highlights the promise
of developing TgCDPK1-targeting compounds with activity against
both acute and chronic stages of parasite infection.3.4. Fatty acid synthesis (FAS) inhibitors
Fatty acids are major components of biological membranes, and
also serve as important signaling molecules. Early work indicated
that T. gondii parasites are able to scavenge lipids, including fatty
acids, from host cells (Charron and Sibley, 2002). Sequencing of
the parasite genome found that T. gondii encodes enzymes of the
so-called FAS II pathway of fatty acid biosynthesis (Seeber and
Soldati-Favre, 2010). Enzymes of the FASII pathway localise to
the apicoplast organelle (Waller et al., 1998; Seeber and Soldati-
Favre, 2010), a non-photosynthetic plastid that is widespread
throughout apicomplexans. Notably, the apicoplast FAS II pathway
differs from the FAS pathway found in the mitochondria of mam-
mals, and also from the cytosolic single multifunctional fatty acid
synthase I (FAS I) enzyme for FAS.
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in the FAS II pathway, led to reduced parasite proliferation
in vitro and reduced virulence in an acute infection of mice
(Mazumdar et al., 2006). Coupled with its absence from the mam-
malian host, this suggested that the FASII pathway may represent a
promising drug target (Fig. 1). Indeed, drugs such as thiolacto-
mycin and triclosan, which target the FASII pathway in bacteria,
were shown to inhibit parasite proliferation (McLeod et al., 2001;
Mazumdar et al., 2006). A more recent study, however, demon-
strated that parasites are able to proliferate in vitro, and cause dis-
ease in an acute infection model, upon the knockout of genes
encoding key FASII enzymes (Liang et al., 2020a, 2020b). In vitro
proliferation in these FASII mutants was slower than in wild type
parasites, and this proliferation defect could be rescued by supple-
mentation with excess fatty acids in the growth medium. This mir-
rors another recent study that revealed that the FASII pathway is
upregulated when parasites are cultured in a lipid-poor growth
medium (Amiar et al., 2020). Together, these findings point to a
considerable degree of metabolic flexibility in lipid acquisition in
T. gondii, suggesting that the FASII pathway may be particularly
important in intracellular niches or stages of infection where fatty
acids in the environment are limiting. Nevertheless, doubts remain
about whether FASII represents a feasible drug target in these
parasites.
3.5. Histone modification inhibitors
Histones are DNA binding proteins that function in packaging
DNA in the nucleus of eukaryotic cells. Post-translational histone
modifications play many and various roles in regulating gene
expression, as well as facilitating DNA replication and repair. In
T. gondii, histone deacetylase (HDAC) and histone acetylase
enzymes are important for controlling gene expression, including
in the interconversion between tachyzoites and bradyzoites
(Saksouk et al., 2005). A HDAC inhibitor, FR235222, targets the
TgHDAC3 protein in T. gondii (Fig. 1), and is a potent inhibitor of
tachyzoite proliferation (Bougdour et al., 2009). Treatment with
FR235222 induces the upregulation of bradyzoite-specific genes
and results in the differentiation of tachyzoites into bradyzoites.
Interestingly, pretreatment of ex vivo bradyzoite-containing cysts
rendered them incapable of converting to tachyzoites when inocu-
lated into mice (Maubon et al., 2010). This suggests that HDAC3
inhibitors hold particular promise in preventing reactivation of
brain cysts. A potential limitation is that FR235222 has only 10-
fold selectivity for T. gondii over host cells. The related HDAC-
targeting compounds W363 and W399, however, exhibit similar
potency to FR235222 in inhibiting parasite proliferation and are
less toxic to human cells (Maubon et al., 2010).
3.6. Isoprenoid biosynthesis inhibitors
Isoprenoids are lipids that contribute to various aspects of cel-
lular biology. In apicomplexan parasites such as T. gondii, they
function as precursors for molecules such as the mitochondrial
electron carrier, CoQ, and a class of lipids termed dolichols, as well
as in the prenylation of proteins that function in the endomem-
brane system (Imlay and Odom, 2014). The basic building blocks
of isoprenoids are two five-carbon molecules termed isopentenyl
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP).
The synthesis of IPP and DMAPP occurs in the apicoplast of api-
complexans via a seven-enzyme pathway termed the methylery-
thritol phosphate (MEP) pathway (Imlay and Odom, 2014). The
MEP pathway, sometimes referred to as the non-mevalonate path-
way, is fundamentally different from the so-called mevalonate
pathway that synthesises IPP and DMAPP in mammalian cells
and, hence, it has been proposed as a promising therapeutic target101in apicomplexans (Fig. 1). Indeed, the antibiotic fosmidomycin,
which inhibits 1-deoxy-D-xylulose-5-phosphate (DOXP) reductoi-
somerase, the second enzyme in the MEP pathway, is a potent inhi-
bitor of proliferation of blood-stage Plasmodium parasites (Jomaa
et al., 1999). Curiously, however, fosmidomycin has no effect on
the growth of T. gondii, despite DOXP reductoisomerase being crit-
ical for T. gondii proliferation and activity of recombinant DOXP
reductoisomerase being sensitive to fosmidomycin (Ling et al.,
2005; Baumeister et al., 2011; Nair et al., 2011). This observation
can be explained by the inaccessibility of fosmidomycin to its site
of action. Overexpression in T. gondii of a bacterial protein capable
of fosmidomycin transport rendered these parasites sensitive to
fosmidomycin both in vitro and in vivo (Nair et al., 2011). Similar
observations of limited fosmidomycin accessibility have been
made in liver-stage Plasmodium parasites (Baumeister et al.,
2011; Nair et al., 2011). To overcome these drug accessibility
issues, a series of so called ‘‘MEPicides”, which are lipophilic ester
prodrugs structurally related to fosmidomycin and designed to
improve entry into target cells, have been synthesised recently;
they were shown to be potent inhibitors of Plasmodium prolifera-
tion in vitro and in vivo (Wang et al., 2018a, 2018b) as well as
being able to inhibit other intracellular pathogens, such as Staphy-
lococcus bacteria, in a transporter-independent manner (Edwards
et al., 2020). It will now be of particular interest to test MEPicides
for anti-Toxoplasma activity.
Following its synthesis in the apicoplast, IPP is exported into the
cytosol where it can be metabolised further to generate a range of
isoprenoids. A dual-function farnesyl diphosphate/geranyl geranyl-
diphosphate synthase (TgFPPS) enzyme in T. gondii generates 15-
and 20-carbon isoprenoids from IPP, and is important for the
biosynthesis of isoprenoids downstream of the DOXP pathway
(Ling et al., 2007). The bisphosphonate compound, risedronate,
inhibits this enzyme (Fig. 1) and shows activity against T. gondii
proliferation in vitro (Martin et al., 2001). Risedronate also
improved the survival of mice infected with tissue cysts by 55%
over 30 days of infection at the highest dose used (Yardley et al.,
2002). Other bisphosphonates with a greater therapeutic index
and potency than risedronate have been identified, with one com-
pound improving the survival of infected mice by up to 80% over a
30 day period (Ling et al., 2005; Shubar et al., 2008).
Genetic disruption of the gene encoding the TgFPPS protein did
not affect proliferation of parasites in fibroblasts in vitro but did
affect proliferation under stress conditions such as growth in
macrophages and when parasites were extracellular (Li et al.,
2013). The dispensability of TgFPPS was attributed to the ability
of T. gondii to scavenge isoprenoids from the host cell. In support
of this, concomitant inhibition of the host mevalonate isoprenoid
biosynthesis pathway using the drug atorvastatin (Fig. 1) increased
survival of mice infected with a TgFPPS knockout strain from 20%
to 90% (Li et al., 2013). Inhibitors of the host mevalonate pathway,
including statins such as atorvastatin, are in widespread use for the
treatment of humans at risk of heart disease. A dual inhibition
strategy using drugs to target both the parasite and host isoprenoid
biosynthesis pathways could yield synergistic effects in vivo, and
future studies examining the therapeutic feasibility of such an
approach for the treatment of T. gondii infections are of particular
interest.
3.7. Protein synthesis inhibitors
The endosymbiotic origin of the apicoplast of T. gondii means
that this compartment houses a bacterially-derived translational
machinery (e.g., 70S ribosomes). Numerous inhibitors of bacterial
translation have been shown to inhibit the proliferation of T. gondii
(Fig. 1) and other apicomplexans (Goodman et al., 2016); for exam-
ple, clindamycin, an inhibitor of the bacterial 50S (large) ribosomal
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has been used in clinical treatment of toxoplasmic encephalitis
patients in combination with pyrimethamine (Dannemann et al.,
1992). Clindamycin-resistant T. gondii strains have mutations in
the large rRNA that is encoded on the apicoplast genome (Camps
et al., 2002), suggesting that clindamycin targets protein transla-
tion in the apicoplast of these parasites.
Parasites treated with clindamycin and other compounds tar-
geting apicoplast translation exhibit a peculiar phenotype known
as delayed death (Fichera et al., 1995; Camps et al., 2002), where
parasite proliferation remains unaffected by drug treatment until
they have egressed from existing host cells and reinvaded new host
cells. This phenomenon is tied to apicoplast loss that occurs upon
treatment with these inhibitors – it appears that the parasites
are able to tolerate apicoplast loss until they reinvade new host
cells, leading to the proposal that a product of apicoplast metabo-
lism is required to establish a new infection (He et al., 2001). Inter-
estingly, co-treatment with clindamycin and the host mevalonate
pathway inhibitor, atorvastatin, results in a more immediate death
phenotype compared with treatment with clindamycin alone
(Amberg-Johnson and Yeh, 2019). This leads to the proposal that
scavenging of host isoprenoids compensates for the loss of the api-
coplast that occurs in the first lytic cycle after clindamycin treat-
ment but that host isoprenoid scavenging is not sufficient to
facilitate longer-term parasite proliferation following apicoplast
loss (Amberg-Johnson and Yeh, 2019).
The macrolide, azithromycin, is another inhibitor of apicoplast
protein translation, and it can be used alone or in combination with
pyrimethamine to treat acute episodes of ocular toxoplasmosis
(Rothova et al., 1998; Bosch-Driessen et al., 2002; Balaskas et al.,
2012). Azithromycin has many favourable properties including
good oral bioavailability, long half-life and fewer side-effects than
pyrimethamine and sulfadiazine (Alday and Doggett, 2017). While
patients experienced fewer side effects with azithromycin treat-
ment than with pyrimethamine and sulfadiazine, one study noted
that 27% of patients experienced recurrence within a year of azi-
thromycin monotherapy (Rothova et al., 1998). This suggests that
azithromycin does not fully eliminate T. gondii cysts in patients.
In agreement with this, while azithromycin treatment prolonged
survival of mice in both acute and chronic mouse infection models
(Araujo et al., 1991a, 1991b; Dumas et al., 1994), azithromycin
treatment of mice chronically infected with T. gondii parasites
did not lessen brain cyst burden compared with controls (Dumas
et al., 1994).
Cytosolic protein synthesis is also a potential target of thera-
peutic intervention in T. gondii (Fig. 1). Studies have revealed that
the conversion of tachyzoites to bradyzoites is concomitant with
the phosphorylation of the a subunit of the T. gondii eukaryotic ini-
tiation factor 2 (TgeIF2; Sullivan et al., 2004; Narasimham et al.,
2008). TgeIF2 has a key role in initiating translation at cytosolic
ribosomes and, as in other organisms, its phosphorylation impairs
cytosolic translation, leading to a global reduction in parasite pro-
tein synthesis (Sullivan et al., 2004; Narasimhan et al., 2008).
Treatment of parasites with the Food and Drug Administration
(U.S.A.)-approved anti-hypertension drug, guanabenz, inhibits
TgeIF2 dephosphorylation, which in turn promotes the formation
of bradyzoite-containing cysts and prevents reactivation into
tachyzoites in vitro (Konrad et al., 2013). Guanabenz treatment
prolonged the survival of mice in an acute infection model by sev-
eral days (Konrad et al., 2013; Benmerzouga et al., 2015). Interest-
ingly, the effects of guanabenz on brain cyst burden seems to vary
between mouse strains, with guanabenz treatment leading to a
decrease in brain cysts in BALB/c mice but leading to an increase
in brain cysts in C57BL/6J mice (Martynowicz et al., 2019). The
authors speculated that these differences could arise from
differences in the reactivation of tissue cysts, differences in102susceptibility of mice to T. gondii infection, and/or differences in
the immune response elicited by these two mouse strains. Regard-
less of the reasons, this study highlights the importance of investi-
gating the contributions of host biology to disease outcomes
following drug treatments.
3.8. Challenges and prospects for better chemotherapeutic treatment
options
While much progress has been made towards identifying new
anti-Toxoplasma chemotherapeutics, there are still many chal-
lenges to translate these findings into better clinical outcomes
for patients. The ideal chemotherapeutic against T. gondii would
cure patients of infection, which would require the compound to
have activity against both the disease-causing tachyzoite form
and the slower-growing bradyzoite form. One of the key challenges
is to obtain a broader understanding of the biology of bradyzoite-
containing tissue cysts, and why drugs fail to eliminate tissue cysts
in patients. Recent advances in facilitating the in vitro differentia-
tion of tachyzoites into bradyzoites en masse may aid in these
efforts (Waldman et al., 2020), although it will be important to ver-
ify that in vitro models recapitulate the biology of bradyzoites and
tissue cysts in vivo. Notably, the replicative capacity and physiol-
ogy of bradyzoites in vivo seems to be more heterogeneous and
dynamic than appreciated previously (Watts et al., 2015; Sinai
et al., 2016), implying that some cysts (potentially those that are
latent/dormant) may be more resistant to drugs than others.
Understanding the causes of this heterogeneity may uncover new
avenues for therapeutic intervention, in particular determining
what factors drive bradyzoites to latency/dormancy.
Another roadblock is the potential for strain-specific effects of
drugs in both T. gondii and mice. A striking example of this is the
mouse strain-dependent disease outcomes observed upon guan-
abenz treatment (see Section 3.7) (Konrad et al., 2013;
Benmerzouga et al., 2015; Martynowicz et al., 2019). These studies
highlight the benefit and, perhaps, necessity of testing compound
efficacy in multiple mouse and T. gondii strains to better inform
the possible outcomes when compounds are progressed to clinical
trials. This also questions the extent to which the performance of a
compound in mouse models resembles the outcome in human
disease.
In the bid to identify new drug targets and novel chemothera-
pies, high throughput screening methods are increasingly utilised
to assess large compound libraries for activity against T. gondii pro-
liferation in vitro (Boyom et al., 2014; Murata et al., 2017; Adeyemi
et al., 2018a). One challenge that limits the progression of hit com-
pounds is differences in their in vitro versus in vivo effectiveness,
as many compounds that show promise in preliminary screens
exhibit unfavorable pharmacokinetic properties or, ultimately, tar-
get processes that are less important for parasite survival in vivo
than in vitro. Structure-activity relationship studies and the devel-
opment of prodrugs with more desirable in vivo properties hold
particular promise in the development of promising ‘‘hits” that
emerge from high throughput screens.
A final challenge is understanding the extent to which anti-Tox-
oplasma treatments can ‘‘piggy-back” on treatment efforts in other
apicomplexan parasites, most notably Plasmodium parasites, for
which extensive drug screening efforts exist. Several current
anti-Toxoplasma agents, including pyrimethamine and atovaquone,
are also potent inhibitors of Plasmodium parasites. Nevertheless,
there are major differences in the host cell types and physiological
environments that these parasites inhabit, and also major differ-
ences in the biology of the different life cycle stages of these para-
sites. This means that drugs that are highly efficacious in one
parasite will not necessarily be potent inhibitors in another para-
site. Emphasising this point, a screen of antimalarial drugs in late
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exhibited only a limited efficacy against T. gondii proliferation
(Radke et al., 2018). As a more specific example, cipargamin, a
potent inhibitor of P. falciparum parasites that targets the PfATP4
sodium pump (Spillman et al., 2013), shows limited efficacy
against T. gondii (Radke et al., 2018; Lehane et al., 2019). This can
be explained by the differences in sodium concentrations experi-
enced by the disease-causing stages of these parasites within their
host cells, with the T. gondii homologue of PfATP4 being dispens-
able for intracellular proliferation (Lehane et al., 2019). Therefore,
while the idea of developing pan-apicomplexan therapeutics that
act on conserved pathways is appealing, it is likely that focusing
early drug development to optimise efficacy against T. gondii will
lead to better therapeutics for treatment of toxoplasmosis.4. Immunotherapies for the control of toxoplasmosis
The activation or suppression of distinct elements of the
immune system via targeted host-directed immunotherapy has
gained significant attention in the field of infectious diseases,
including toxoplasmosis (Kaufmann et al., 2018a, 2018b; Singh
et al., 2019). Immunotherapies are less prone to the emergence
of resistance and often have fewer side effects compared with
antimicrobial drugs. Whilst there are currently no immunothera-
pies in use for human toxoplasmosis, murine models have pro-
vided insight that may prove crucial for future developments
(Fig. 2). In the following section, we review recent research
advances in immunotherapies against toxoplasmosis, including
the role of passive immunisation, monoclonal antibody therapy,
chimeric antigen receptor (CAR) T cells, cytokines and chemokines,
immunomodulatory drugs and trained immunity, any of which
could conceivably become the basis for future treatments of
immunosuppressed people.4.1. Passive immunisation, monoclonal antibodies and CAR T cells
Passive immunisation, the transfer of polyclonal antibodies
from immune sera (Fig. 2A), has been used to treat and prevent
infectious diseases such as tetanus, rabies and hepatitis B
(Sparrow et al., 2017). Early adoptive transfer studies in a hamster
model of T. gondii infection suggested that antibodies contribute
only marginally to protection after transfer (Frenkel, 1967). These
findings laid the foundation for the concept that immunity to T.
gondii is dominated by IFN-c producing CD8+ T cells (Suzuki and
Remington, 1990; Kang et al., 2000; Sayles et al., 2000; Casciotti
et al., 2002). However, it was later shown that, in murine toxoplas-
mosis, antibodies contribute to controlling long-term persistence
and vaccination-induced resistance (Kang et al., 2000; Sayles
et al., 2000). With the more recent and widespread use of mono-
clonal antibody (mAb) therapy in the treatment of cancer (Byun
et al., 2017), passive immunisation with mAbs in toxoplasmosis
has been revitalised. It was shown that the transfer of human
mAb Fab fragments specific to the T. gondii surface antigen 1
(SAG1) protein into mice significantly improved survival rates
(Fu et al., 2011). Similarly, the transfer of mAbs against dense gran-
ule proteins GRA2, GRA6 or nucleoside triphosphate hydrolase-II
into mice promoted prolonged survival (Cha et al., 2001; Tan
et al., 2010). Even though none of these transfers provided sterile
immunity, it is possible that the identification of additional
bradyzoite- and cyst wall-specific antigens, such as SRS9, CST1
and MAG2 (Kim et al., 2007; Tomita et al., 2013; Tu et al., 2020),
may pave the way for future combination mAb therapies targeting
several stage-specific molecules for attachment, invasion, prolifer-
ation and persistence simultaneously (Fig. 2B). Similarly, mAbs
that target the inhibition of receptors, such as CTLA-4 and PD-1,103on CD8+ T cells and natural killer (NK) cells have been shown to
enhance immunity during chronic T. gondii infection (Hunter
et al., 1997; Bhadra et al., 2011, 2012; Xiao et al., 2018), though
these findings require further validation (Splitt et al., 2018).
Although cellular immunotherapies, such as the transfer of
immune CD8+ T cells and NK cells, can protect animals from lethal
T. gondii challenge (Casciotti et al., 2002; Ivanova et al., 2019),
these strategies are not suitable for large scale human application.
However, the advent of commercial-scale CAR T cell and NK cell
therapy may provide a new avenue for cell-mediated immunother-
apy in toxoplasmosis (Maldini et al., 2018; Liu et al., 2020). CAR T
cell therapy involves the transfer into patients of genetically mod-
ified T cells that not only recognise specific protein targets but also
co-express T cell activation functions in a single engineered recep-
tor. CAR T cell therapy has revolutionised cancer treatment over
the last decade and, despite non-cancer applications still being in
their infancy, one could envisage that the re-engineering of
patient-derived CD8+ T cell or NK cell receptors specific for stage-
specific T. gondii antigens could significantly improve feasibility
and success of cellular immunotherapy for (latent) toxoplasmosis
(Fig. 2C). Nevertheless, a vigilant evaluation of these immunother-
apies in the context of infection will be required, as neurological
complications and disseminated toxoplasmosis have been reported
in CAR T cell-treated patients (Kersten et al., 2019; Kator et al.,
2020).
4.2. Cytokines
Immunity to toxoplasmosis is critically dependent on ILs and
IFN-c, in particular the IL-12/IFN-c axis (Yarovinsky, 2014); many
studies have demonstrated beneficial outcomes after the delivery
of recombinant IL-12 (Hunter et al., 1995; Araujo et al., 1997) or
IFN-c (Suzuki et al., 1988; Suzuki et al., 1990; Benedetto et al.,
1991; Delemarre et al., 1993; Delemarre et al., 1994) in mouse
models of toxoplasmosis and in ex vivo infection of human cells.
Similarly, IL-18, formerly known as IFN-c enhancing factor, also
plays a critical role in immunity to T. gondii, by synergising with
IL-12 (Cai et al., 2000). The development, expansion and survival
of IFN-c-producing cell types depends on the c chain cytokines,
IL-2, IL-7 and IL-15 and, thus, immunotherapies based on said
cytokines have also shown improved outcomes of toxoplasmosis
in animal models (Fig. 2D). While the exact role of IL-15 in immu-
nity to T. gondii remains somewhat unresolved (Khan et al., 2002;
Lieberman et al., 2004), IL-2 deficient mice are highly susceptible
to T. gondii infection (Villegas et al., 2002), and administration of
recombinant IL-2 enhances survival of Toxoplasma-infected mice
(Sharma et al., 1985; Shirahata et al., 1993). Delivery of recombi-
nant IL-15 also protects against lethal infection by enhancing
IFN-c production (Khan and Casciotti, 1999; Khan and Kasper,
1996) but IL-15 deficient mice are able to develop protective
immunity (Lieberman et al., 2004). IL-7 and IL-15 appear to syner-
gise during acute infection (Kasper et al., 1995; Bhadra et al., 2010),
although the recall response of memory CD8+ T cells to T. gondii is
almost exclusively dependent on IL-15 (Bhadra and Khan, 2012).
IL-2 and IL-15 are presented to the cytokine receptor complex
beta and the common c chain in the context of cell-bound high-
affinity alpha chains of the cytokine receptor (Stoklasek et al.,
2006; Stonier and Schluns, 2010). This process has been termed
trans-presentation. Combining IL-2 with anti-IL-2 mAbs to form
an IL-2 complex (IL2C) or combining IL-15 with a chimeric receptor
(IL-15RaFc) to form an IL-15 complex (IL15C) significantly
enhances the biological activity of these cytokines in vivo
(Boyman et al., 2006; Votavova et al., 2014). The binding site of
the anti-IL2 mAb used in the IL2C determines whether a preferen-
tial expansion of regulatory T cells (TReg) or CD8+ T cell and NK cells
occurs; anti-IL-2 mAb JES6-1A12 causes expansion of TReg cells;
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NK cells (Boyman et al., 2006; Shevach, 2012). In animal studies,
JES6-1A12-containing IL2C improved control of RH strain T. gondii
infection (Akbar et al., 2015) and reduced immunopathology and
morbidity during acute type II T. gondii ME49 infection
(Oldenhove et al., 2009), likely by preventing the competition for
bioavailable IL-2 between regulatory and effector T cells. We have
also shown recently that S4B6-containing IL2C-mediated expan-
sion of non-CD4 immune cells that produce IFN-c can be harnessed
to rescue mice from acute lethal toxoplasmosis (Kupz et al., 2020).
Intriguingly, although this IL-12- and IL-18-dependent effect of
treatment with SB46-IL2C leads to reduced acute pathology, it does
so without affecting TReg cells or parasite burden. Together, these
IL2C studies suggest that cytokine complex immunotherapy may
be a viable future adjunct treatment in the context of chronic tox-
oplasmosis, in particular for immunosuppressed people with
impaired CD4+ T cells, e.g., as caused by HIV co-infection in AIDS
(Fig. 2E). However, caution is needed because data on the clinical
use of IL2C and IL15C treatments in humans are lacking and it
needs to be acknowledged that treatment with cytokine complexes
could lead to hyperinflammatory responses. Such an undesirable
potential outcome should be taken into careful consideration
before embarking on translational studies in humans.4.3. Chemokines
Many parasitic infections, including toxoplasmosis, are charac-
terised by excessive or imbalanced inflammation and pathology
(Menzies et al., 2016). These events are tightly linked to the
recruitment, influx and persistence of leukocytes to the site of
infection, events that are regulated by chemokines and their recep-
tors (Menzies et al., 2016). Similar to most intracellular pathogens,
T. gondii benefits from leukocyte recruitment, as it can use infected
cells to spread through the host (Da Gama et al., 2004; Lambert
et al., 2009). Hence, interfering with the chemokine-chemokine
receptor axis may provide novel targets for host-directed therapies
(Fig. 2F). To illustrate, mouse studies have shown that the absence
of chemokine receptor type 5 (CCR5) leads to a reduction in tissue
damage due to reduced NK cell recruitment and IFN-c production,
but also to an increased parasite burden (Khan et al., 2006). CCR5
signalling is also involved in the T. gondii-induced interruption of
pregnancy in mice (Nishimura et al., 2017), and human polymor-
phisms in CCR5 have been linked to a greater risk of developing
ocular toxoplasmosis (de Faria Junior et al., 2018). The T. gondii
secreted effector molecule, cyclophilin 18 (TgCyp18), binds to
CCR5 and mimics CCR5 ligand binding (Aliberti et al., 2003), fur-
ther supporting the idea that CCR5 activation favours T. gondii sur-
vival. However, no therapeutic or prophylactic treatments with
antibodies or inhibitors targeting CCR5 or its ligands CCL3, CCL4
and CCL5 in the context of toxoplasmosis have been reported toFig. 2. Summary of potential immunotherapies for the control of toxoplasmosis. (A) Iso
individuals could be used for passive immunisation. (B) Monoclonal antibody (mAb) ther
bradyzoites and the cyst wall. (C) Isolation of T and natural killer (NK) cells from T. go
antigen receptors (CAR) specific for T. gondii epitopes. Expanded chimeric antigen rec
quiescent and actively replicating parasites. (D) The synergistic effects of IL-2, IL-7, IL-12
interferon-c production by T cell subsets and natural killer cells could be used to boost
could be used to expand interferon-c (IFN-c)-producing immune cells to boost immunity
immunopathology and morbidity. (F) Interference with the chemokine-chemokine recept
during acute toxoplasmosis. The T. gondii secreted effector molecules, TgCyp18, SAG1 an
secretion by epithelial cells, respectively. Blocking these effector molecules in addition
excessive recruitment, influx and persistence of leukocytes to the site of infectio
immunomodulatory drugs (IMiDs) and natural products such as lectins, lactoferrin and
treatments of toxoplasmosis. (H) A further understanding of trained immunity in the con
imprinting in immune cells and epithelial cells. Muramyl dipeptide and b-glucan in com
toxoplasmosis. See Section 4 for further details.
105date. Given that CCR5 receptor antagonism inhibits hepatitis C
virus replication (Blackard et al., 2019) and limits the progression
of gastric cancer (Aldinucci and Casagrande, 2018), further studies
into its effect on toxoplasmosis are warranted.
CCL2, CCL3, CCL4 and CCL5 are produced by intestinal cells after
they become exposed to tachyzoites (Gopal et al., 2011). In partic-
ular, the parasite-derived molecules GRA24 and SAG1 have been
implicated in this process (Rachinel et al., 2004; Brenier-Pinchart
et al., 2006; Braun et al., 2013), indicating that T. gondii actively
manipulates chemokine secretion pathways to its advantage. The
double-edged sword of leukocyte recruitment for the initiation of
immunity against T. gondii and the parasite’s requirement to
induce inflammation, is also demonstrated by studies using CCR1
and CCR2 knockout mice, both of which are highly susceptible to
lethal toxoplasmosis (Khan et al., 2001; Dunay et al., 2008). Che-
mokine and anti-chemokine therapies are actively being pursued
in the field of inflammatory diseases (Castellani et al., 2007;
Mohit and Rafati, 2012; Ambade et al., 2019) and cancer (Ruffini
et al., 2007; Arakaki et al., 2016; Lim et al., 2016). However, similar
to CCL3, CCL4 and CCL5, no targeted therapies with CCL2, CCL7,
CCL23, or synthetic CCR1 or CCR2 agonists and antagonists have
been reported in the context of toxoplasmosis. This area of
research would benefit from further investigations.4.4. Immunomodulatory drugs
Immunomodulatory drugs comprise different classes of com-
pounds with direct or indirect impact on the immune system
(Gao et al., 2020). The imide-containing class of immunomodula-
tory drugs (IMiDs), such as thalidomide and several analogues,
are widely used in the treatment of autoimmune diseases and can-
cer (Abe and Ishida, 2019; Fuchs, 2019). To date, none of these
IMiDs have been reported to have an impact on toxoplasmosis.
However, there is growing interest in deciphering the role of vari-
ous immunomodulatory compounds derived from chemical
libraries as well as from natural products on infectious diseases,
including toxoplasmosis (Sepulveda-Arias et al., 2014; Sharif
et al., 2016) (Fig. 2G); for example, in one study, it was shown that
treatment of mice with ursolic acid, a compound commonly found
in various fruits, increased a number of critical anti-toxoplasmosis
cytokines in a mouse model of toxoplasmosis (Choi and Lee, 2019).
Similarly, beneficial effects on murine toxoplasmosis have been
reported after treatment with lectins (Ramos et al., 2016), Echi-
nacea purpurea extracts (Gasparotto Junior et al., 2016) and lacto-
ferrin (Anand et al., 2015).4.5. Trained immunity
In recent years, the concept of ‘‘trained immunity” has gained
significant attention (Netea et al., 2016, 2020). It has been shownlation and transfer of polyclonal antibodies from sera of Toxoplasma gondii immune
apy with mAbs could be used to target different antigens expressed by tachyzoites,
ndii-infected individuals followed by re-programming of these cells with chimeric
eptors T and natural killer cells are re-infused into infected individuals to target
, IL-15 and IL-18 in mediating development, differentiation, expansion, survival and
immunity to T. gondii. (E) Cytokine complexes of IL-2/anti-IL-2 and IL-15/anti-IL-15
against acute toxoplasmosis. Expansion of regulatory T cells could be used to reduce
or axis may be used to target excessive and imbalanced inflammation and pathology
d GRA24, either bind to CCR5 and mimic CCR5 ligand binding or induce chemokine
to CCL2, 3, 4, 5, 7 and 23, as well as their receptors, CCR1, 2 and 5, may prevent
n. (G) Immunomodulatory compounds such as the imide-containing class of
ursolic acid, which stimulate cytokines and immune cells, could be used as adjunct
text of toxoplasmosis may reveal potential therapies to specifically target epigenetic
bination with spiramycin have shown therapeutic potential in murine models of
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and b-glucan have a strong effect on ‘‘training” hematopoietic stem
cells and innate immune cells via epigenetic imprinting (Kaufmann
et al., 2018a, 2018b). This trained immunity appears to be the rea-
son for adaptive immunity-independent protection against a vari-
ety of viral, bacterial and parasitic pathogens (Arts et al., 2018; Dos
Santos et al., 2019; Tarancon et al., 2020). To date, no study has
addressed the specific role of trained immunity in treating, pre-
venting or ameliorating T. gondii infection and disease, whether
acute or latent. However, given the explosion of research activity
in this field, it appears to be only a matter of time before the impact
of trained immunity on toxoplasmosis will be investigated
(Fig. 2H). In that context, it is important to note that Krahenbuhl
et al. (1981) demonstrated that pre-treatment of mice with the
synthetic adjuvant muramyl dipeptide afforded resistance to sub-
sequent T. gondii challenge. The authors of that study concluded
that the protection was independent of enhanced antibody produc-
tion or macrophage activation, and must have been due to a yet to
be identified mechanism. Interestingly, independently of assessing
the impact on immunity, a synergistic effect of b-glucan with spi-
ramycin in the treatment of toxoplasmosis has also been reported
previously (Buyukbaba Boral et al., 2012). It has also been proposed
that human T. gondii infection itself may have long-term effects on
the phenotype and responsiveness of monocytes, implying a train-
ing effect that may also impact immunity to unrelated pathogens
(Ehmen and Lüder, 2019).5. Vaccination for the control of toxoplasmosis
Vaccination has been used extensively to control infectious dis-
eases worldwide (Doherty et al., 2016). Due to the complexity of
the life cycle of T. gondii and the parasite’s ability to infect any
warm-blood animal, the challenge to develop a vaccine to control
toxoplasmosis involves consideration of: (i) which stage of the par-
asite life cycle and, hence, which host(s) to target; (ii) which para-
site antigens to target; and (iii) the mode of delivery.
A vaccine for direct use in humans should, ideally, protect
against both the acute and chronic phases of infection, needing
to prevent the severe consequences of ocular toxoplasmosis, con-
genital toxoplasmosis caused by a primary infection in pregnant
women, and the mortality caused by the reactivation of latent par-
asites in immunosuppressed individuals (Tenter et al., 2000;
Machala et al., 2015; El Bissati et al., 2018). It is debatable whether
a single vaccine could achieve all these requirements.
A vaccine targeting T. gondii in livestock would not only need to
prevent bradyzoite cyst formation in order to minimise transmis-
sion of the parasite to humans through consumption of under-
cooked meat (Tenter et al., 2000) but would also need to reduce
the economic loss caused by animal abortion, especially in sheep
and goats (Stelzer et al., 2019), to encourage widespread use.
Again, these different requirements might necessitate the identifi-
cation of different targets in T. gondii and require different modes
of delivery.
A vaccine targeting felids, the only definitive host of T. gondii,
would be able to stop the shedding of highly infective oocysts into
the environment and, consequently, reduce the incidence of infec-
tion via ingestion in both livestock and humans (Frenkel and
Smith, 1982; Innes et al., 2009; Torrey and Yolken, 2013). Mathe-
matical modelling highlights the attractiveness of the cat as a tar-
get for vaccination in order to prevent toxoplasmosis in livestock
and humans (Mateus-Pinilla et al., 2002; Arenas et al., 2010;
Jiang et al., 2012; Turner et al., 2013; Sykes and Rychtář, 2015;
Bonačić Marinović et al., 2020) but the form and means of delivery
to achieve sufficient coverage of such a vaccine arguably presents a
potential obstacle to success (Bonačić Marinović et al., 2020).1065.1. Anti-Toxoplasma vaccines for intermediate hosts
5.1.1. Anti-Toxoplasma vaccines targeting humans
Virtually all individuals are at risk of acquiring toxoplasma
infection at some point in their lifetime, therefore a vaccine to pre-
vent toxoplasmosis in humans would benefit all (Tenter et al.,
2000). Ideally, a T. gondii vaccine should target young girls before
they reach fertile age and induce a protective immune response
able to prevent the vertical transmission of the parasite from the
mother to the unborn child. Such a vaccine would reduce the glo-
bal incidence of congenital toxoplasmosis, which is estimated to be
1.5 cases per 1,000 live births (~190,000 new cases every year)
(Jones et al., 2001; Torgerson and Mastroiacovo, 2013). A vaccine
to prevent acute and chronic toxoplasmosis is desirable. Such a
vaccine would prevent the severe illness caused by an acute infec-
tion in immunocompromised individuals, as well as protect against
the life-threatening reactivation of latent bradyzoites present in
tissue cysts of individuals who acquired toxoplasmosis when
healthy but become immunocompromised afterwards (Pott and
Castelo, 2013; Stajner et al., 2013; Wang et al., 2017).
There are no reports of T. gondii vaccine studies in humans.
There is, however, a long list of experimental vaccines that have
been tested recently in murine models, examples of which are
summarised in Table 2 and Fig. 3. As is the case for any intermedi-
ate host, mice can be infected by oral administration of oocysts or
cysts containing bradyzoites, mimicking natural routes of infec-
tion, or by the artificial injection of tachyzoites. Experimental mod-
els established in mice include acute and lethal T. gondii infection,
the formation of bradyzoite tissue cysts in muscles and brain, and
congenital toxoplasmosis (Subauste, 2012). Several vaccine candi-
dates have been investigated including SAGs, rhoptry proteins
(ROP), microneme proteins (MIC), GRA and other proteins secreted
by tachyzoites (Fig. 3). Similarly, different formulations, adjuvants,
immunisation routes and schedules have been tested, spanning
killed or live attenuated parasites, subunit vaccines, recombinant
proteins, DNA vaccines and live vectors to deliver T. gondii antigens
(Fig. 3). Despite showing some promise – most candidates report-
ing some ability to reduce cyst formation and prolong survival of
the host – there is no report of progression of a vaccine tested in
mice to human clinical trials.
To date, the only commercial vaccine against T. gondii is based
on an attenuated strain designed to prevent abortion in sheep
which, due to potential safety and regulatory issues associated
with a possible reversion to fully virulent parasites, is not consid-
ered suitable for administration to humans (Innes et al., 2019).
However, provision of the genomes of the main T. gondii strains
(Lorenzi et al., 2015) and transcriptomic data sets of different
stages of the parasite life cycle (Behnke et al., 2014; Hehl et al.,
2015; Ramakrishnan et al., 2019), combined with advances in the
use of CRISPR/Cas9 genome editing strategies (Shen et al., 2017;
Sidik et al., 2018; Markus et al., 2019; Young et al., 2019) that allow
targeted and selectable marker-free deletion of genes, may lead to
the development of optimised attenuated strains with reduced
risks of reversion. Indeed, the prospects for development of a live
attenuated vaccine for humans and other intermediate hosts have
been enhanced by recent discoveries concerning how stage differ-
entiation is regulated at a molecular level (Farhat et al., 2020;
Waldman et al., 2020). In particular, the identification of a single
transcription factor (the Myb-like transcription factor, BFD1) as a
master-regulator for differentiation from tachyzoite to bradyzoite
(Waldman et al., 2020) theoretically paves the way for develop-
ment of a live vaccine incapable of forming cysts (Kochanowsky
and Koshy, 2020). In addition, an advantage of CRISPR/Cas9 in
the context of producing attenuated vaccine strains is that genes
can be, effectively, knocked out without introducing foreign DNA
into the parasite. This means that these strains would not neces-
Table 2
Examples of recent experimental murine vaccines against Toxoplasma gondii.
Live Attenuated Vaccines









Vaccine Trial Results Summary
CDPK2a PruDcdpk2 RH, PRU Kunming IgG, Th1/Th2
cytokines
Protection of host against lethal challenge; partial
reduction of brain cyst numbers.
LDH1 and LDH2b,c PruDldhb
ME49Dldh c
RHb
RH, ME49, VEG and







Protection of host against lethal challengeb
Protection of host against lethal challenge; partial
reduction of brain cyst numbersc
Gra17 and NPT1d RHDgra17Dnpt1 RH, PRU Kunming IgG, IFN-c, IL-
2, IL-10 and
IL-12
Protection of host against lethal challenge; partial
reduction of brain cyst numbers; partial protection
against congenital toxoplasmosis
Tyrosine kinase-like 1e RHDtkl1 RH, PRU Kunming IgG1, IgG2a,
IFN-c, IL-2
Protection of host against lethal challenge; partial
reduction of brain cyst numbers; partial protection
against congenital toxoplasmosis









Vaccine Trial Results Summary
Recombinant GRA2g Monophosphorryl lipid
A (MPL)















BALB/c RH BALB/c IgG, IFN-c, IL-
12, IL-10
Prolonged survival of host








Protection of host against lethal challenge; partial
reduction of brain cyst numbers





RH BALB/c IgG1, IgG2a,
IFN-c, IL-2
Prolonged survival of host














Vaccine Trial Results Summary
GRA7 and ROP2m RH BALB/c IgG2a, IFN-y Prolonged survival of host
T. gondii profilin (TgPF)n IL-15 PRU Kunming IgG, IgG2a,
IFN-c, IL-2,
IL-4, IL-10
Partial reduction of brain cyst numbers
Perforin-like protein (PLP1)
and ROP18o
IL-18 PRU Kunming IgG2a, IL-2,
IL-12, IFN-c
Prolonged survival of host; partial reduction of brain
cyst numbers
ROP22p RH BALB/c IgG1, IgG2a,
IL-2, IFN-c
Prolonged survival of host; partial reduction of brain
cyst numbers
ROP21q RH, PRU BALB/c IgG1, IgG2a,
IFN-c
Prolonged survival of host; partial reduction of brain
cyst numbers
ROP5 and ROP18r IL-33 RH Kunming IgG2, IFN-c,
IL-2, IL-12
Prolonged survival 0f host; partial reduction of brain
cyst numbers
ROP 8 epitopess RH BALB/c IgG1, IgG2a,
IFN-c
Prolonged survival of host








Vaccine Trial Results Summary
Apical membrane antigen 1
(AMA1)t
Adenovirus vaccine RH BALB/c IFN-c, IL-4 Increased survival of host
a Wang et al. (2018a).
b Abdelbaset et al. (2017).
c Xia et al. (2018).
d Liang et al. (2020a), Liang et al. (2020b).
e Wang et al. (2020a).
f Wang et al. (2020b).
g Babaie et al. (2018).
h Picchio et al. (2018).
i Huang et al. (2019).
j Guo et al. (2018).
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k Roozbehani et al. (2018).
l Kim et al. (2020).
m Vazini et al. (2018).
n Gao et al. (2018).
o Chen et al. (2018).
p Zhang et al. (2019).
q Zhang et al. (2018).
r Zhu et al. (2020).
s Foroutan et al. (2020).
t Jia et al. (2018).
Fig. 3. Summary of some recent experimental murine vaccines against Toxoplasma gondii infection. Targets include proteins that function in the micronemes, rhoptries, dense
granules, cytosol, nucleus, plasma membrane, or parasitophorous vacuole membrane. Vaccine strategies include the production of protein subunit vaccines, DNA vaccines,
adenovirus vaccines, and attenuated parasite strains (refer to key for symbols). See Section 5 and Table 2 for further details.
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many countries (Zhang et al., 2020).
Another approach to vaccine development has been to combine
bioinformatic tools with immunological approaches. Such studies
have focussed on identifying peptide epitopes from proteins108secreted during infection with T. gondii that can access the major
histocompatibility complex class I pathway. These peptides can eli-
cit the production of IFN-c from CD8+ T cells in peripheral blood
mononuclear leukocytes of humans who are T. gondii seropositive
(Cong et al., 2010, 2011). Immunisation of human leukocyte anti-
N.C. Smith, C. Goulart, J.A. Hayward et al. International Journal for Parasitology 51 (2021) 95–121gen (HLA) transgenic mice with multi-epitope DNA or protein vac-
cines in combination with a universal CD4+ epitope peptide and
adjuvant induced high levels of IFN-c and protected mice against
challenge with type II parasites (Cong et al., 2010, 2011; El
Bissati et al., 2016). Although the high polymorphism of HLA mole-
cules in the human population may be an obstacle for epitope-
based vaccines, studies have demonstrated that the specificity of
peptide-binding shared by the HLA supertypes A02, A03, and B07
corresponds to ~90% of the world’s population (Barber et al.,
1995; Sidney et al., 1995).
5.1.2. Anti-Toxoplasma vaccines targeting livestock
The only commercial T. gondii vaccine (Toxovax) was devel-
oped over three decades ago in New Zealand for control of abortion
in sheep (O’Connell et al., 1988; Buxton and Innes, 1995). Toxovax
consists of attenuated tachyzoites of the S48 strain of T. gondii,
which after over 3000 passages in mice lost its ability to develop
bradyzoite tissue cysts (Buxton, 1993). This vaccine is recom-
mended for immunisation of ewes as a single intramuscular injec-
tion at least 4 weeks before mating. Following immunisation, the
attenuated parasites undergo limited replication cycles, mimicking
a natural infection, and this is able to induce long-lasting protec-
tion, likely involving CD4+ and CD8+ cell responses along with
IFN-c production (Buxton et al., 1994). Toxovax is commer-
cialised through MSD Animal Health and is available in the UK, Ire-
land, France and New Zealand.
Vaccination with the S48 strain of T. gondii impairs the forma-
tion of bradyzoite tissue cysts in animals subsequently treated
with wild type parasites; immunisation of lambs with the S48
strain reduced the presence of parasites detected by PCR in the
heart (by 75%) and skeletal muscles (by 82%) of lambs challenged
with wild type oocysts (Katzer et al., 2014). Similar results were
observed in pigs immunised with the S48 strain before challenge
with wild type oocysts (Burrells et al., 2015). A bioassay showed
increased survival (48.5%) of mice that received tissue samples
from vaccinated pigs compared with mice that received porcine
tissue samples from the control group (Burrells et al., 2015).
Although S48 vaccination did not completely prevent tissue cyst
formation following challenge in lambs and pigs, these studies
indicate that a vaccine able to reduce the cyst burden in livestock
may reduce the risk of infection of humans through consumption
of undercooked meat (Katzer et al., 2014; Burrells et al., 2015).
Since the approval of Toxovax, other live attenuated and inac-
tivated parasites have been investigated in order to develop an
improved vaccine to prevent sheep abortion and protect against
tissue cyst development. Immunisation of ewes with tachyzoites
of a strain of T. gondii, wherein MIC1 and MIC3 were knocked out
(MIC1-3KO) 2 months before mating, induced humoral responses
and reduced the abortion of lambs in ~72% of ewes after a chal-
lenge with wild type oocysts mid-gestation (Mevelec et al.,
2010). However, MIC1-3KO tachyzoites were reported to persist
as tissue cysts in immunised animals (Mevelec et al., 2010). A
temperature-sensitive mutant (TS-4) of the RH isolate of T. gondii
(Pfefferkorn and Pfefferkorn, 1976), which does not persist as tis-
sue cysts in the tissues of mice (Waldeland et al., 1983), was eval-
uated for its ability to prevent tissue cysts in pigs (Lindsay et al.,
1993). A bioassay showed that immunisation of pigs with TS-4
tachyzoites by subcutaneous or intravenous routes did not protect
against bradyzoite cyst formation in the tissues of pigs challenged
with wild type oocysts (Lindsay et al., 1993; Dubey et al., 1994).
Similarly, oral administration of oocysts inactivated by 137Cs
gamma irradiation (0.3 or 0.4 kGy) did not prevent bradyzoite tis-
sue cyst formation in pigs challenged with live oocysts (Dubey
et al., 1998).
Extracts or purified fractions of T. gondii parasites in combina-
tion with adjuvants have been investigated as subunit vaccines.109Microspheres containing proteins from a crude extract of RH strain
tachyzoites encapsulated into poly(D,L-lactide-co-glycolide) were
investigated as an intranasal vaccine for sheep with and without
cholera holotoxin (Stanley et al., 2004). Although both systemic
and mucosal humoral responses, together with cell-mediated
immunity, were observed, immunisation with microspheres con-
taining T. gondii proteins failed to protect sheep against clinical
signs of infection upon challenge with oocysts of the M3 strain of
T. gondii. Western blot analysis demonstrated that the main anti-
body elicited after immunisation was reactive against a protein
of approximately 30 kDa, likely to be the major surface antigen
of the parasite, SAG1 (Stanley et al., 2004). This suggests that
SAG1 antibodies are not sufficient to protect against infection. In
pigs, subcutaneous immunisation with two doses of crude rhoptry
proteins formulated as immunostimulating complexes (ISCOMs),
induced a systemic IgG response. Following challenge with oocysts,
the animals immunised with rhoptry proteins showed the same
clinical signs of infection as control pigs (including fever, secretions
from the eye, coughing and loss of appetite) and only 20% of vacci-
nated pigs did not develop tissue cysts as indicated by a bioassay in
mice (Garcia et al., 2005). Similarly, a further investigation showed
that crude ROPs administered by the intranasal route in combina-
tion with the adjuvant, Quil A, did not induce strong humoral or
cellular immune responses prior to challenge infection, and only
one of four pigs tested negative for T. gondii by bioassays post-
challenge (da Cunha et al., 2012). In contrast, another study
showed that immunisation of pigs with a mixture of tachyzoite
excretory/secretory antigens induced humoral and cellular
immune responses, including IFN-c and IL-4, and prevented the
development of tissue cysts in four out of five pigs following chal-
lenge with tachyzoites injected intraperitoneally (Wang et al.,
2013). However, the small number of animals tested and the
unnatural route of challenge infection combined with the use
FCA, a powerful inducer of cell-mediated immune responses that
is not used commercially due to safety issues, restricts evaluation
of this study’s practical implications.
DNA vaccines encoding several T. gondii antigens have been
investigated for their ability to induce an immunological response
in sheep and pigs. Immunisation of sheep with a DNA vaccine
encoding the bradyzoite-specific antigen, MAG1, alone or co-
expressed with the cytokine, IL-6, induced a specific humoral
response (Hiszczynska-Sawicka et al., 2010). Comparison of the
immune response in sheep immunised with a DNA vaccine encod-
ing SAG1 or ROP1 combined with unmethylated cytosine-
phosphate-guanosine oligodeoxynucleotide motifs showed that
ROP1-encoding DNA, but not SAG1-encoding DNA, was able to
induce humoral and IFN-c responses (Li et al., 2010). Similarly,
plasmids encoding for ROP1 in fusion with CD154, a co-
stimulatory molecule expressed by activated T-cells, induced a
mixed Th1/Th2 response in sheep, with higher IFN-c levels than
was induced by plasmids encoding ROP1 protein only
(Hiszczynska-Sawicka et al., 2011a). DNA vaccines encoding
GRA1, GRA4, GRA6 or GRA7 showed that GRA7 can stimulate the
ovine immune system and was able to induce IFN-c and IgG2
responses (Hiszczynska-Sawicka et al., 2011b). In pigs, immunisa-
tion with a DNA vaccine encoding for GRA1 and GRA7 induced
antibodies and cellular immune responses to both proteins
(Jongert et al., 2008). Unfortunately, none of the DNA vaccines
described above have ever been tested for efficacy against T. gondii
challenge.
5.2. Anti-Toxoplasma vaccines for the definitive host
Felids are the only definitive host of T. gondii. After a primary
infection with T. gondii, cats may shed millions of oocysts that
can persist in soil and water as sources of infection for many
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usually, no oocysts are observed in the faeces of challenged cats
indicating that, even after a single infection, cats develop an
immune response that is able to prevent repeated oocyst shedding
(Dubey, 1995). Moreover, there is evidence that this immunity
cross-protects against heterologous strains (Freyre et al., 2007).
Thus, although the nature of this immune response is not known,
there are grounds to believe that a vaccine that is able to block
oocyst shedding by cats would reduce the number of oocysts in
the environment and, consequently, reduce the prevalence of tox-
oplasmosis, providing that issues related to vaccine coverage of
pets and stray or feral cats could be resolved.
Attempts to develop recombinant and subunit vaccines to pre-
vent the shedding of oocysts by cats have been few and have
shown only limited promise. A recombinant feline herpesvirus
type 1 (FHV1) expressing the T. gondii ROP2 protein reduced the
bradyzoite cyst burden in the brains of cats but failed to prevent
oocyst shedding after challenge with bradyzoite-containing cysts
of the Beverley strain (Mishima et al., 2002). Crude rhoptry pro-
teins purified from tachyzoites were investigated as a vaccine can-
didate in combination with the adjuvant Quil A; administration via
the intranasal or rectal routes followed by oral challenge with
bradyzoite cysts of ME49 strain showed some ability to prevent
oocyst shedding by cats compared with a control group receiving
BSA and Quil A (Zulpo et al., 2012). Similarly, immunisation of cats
with recombinant ROP2 plus Quil A via the nasal route reduced the
total number of oocysts in only 23.9% of cats compared with the
control group receiving BSA and the adjuvant (Zulpo et al., 2017).
In contrast, immunisation of cats by infection with live attenu-
ated strains of T. gondii has proven highly effective at preventing
oocyst shedding. The T-263 strain of T. gondii, which is a
chemically-induced mutant that develops through to micro- and
macrogametes but lacks the ability to produce oocysts (Dubey,
2017), was the first reported live attenuated vaccine investigated.
Oral administration of two doses of T-263 tissue cysts or brady-
zoites released by pepsin digestion induced antibody responses
and prevented oocyst shedding in 84% (Frenkel et al., 1991) or
100% (Freyre et al., 1993) of kittens after challenge with an oocyst
producing strain. The efficacy of the live attenuated T-263 strain as
a transmission-blocking vaccine was also investigated in a long-
term field trial in swine farms in the U.S.A. (Mateus-Pinilla et al.,
1999). Cats present on these swine farms were caught and immu-
nised by infection with bradyzoites of the T-263 strain. Immunisa-
tion of cats significantly reduced T. gondii infection in finishing pigs
on these farms across time (Mateus-Pinilla et al., 1999). Despite the
promising results achieved with the T-263 strain of T. gondii, diffi-
culties associated with large-scale production of bradyzoites, cold
chain transportation, and perceived risks to people handling and
administering the vaccine inhibited its commercialisation
(Choromanski et al., 1995).
Given the manner of its derivation, the T-263 strain of T. gondii
is likely to possess multiple mutations. However, apart from some
documentation ~40 years ago of enzymatic perturbations
(Pfefferkorn, 1978; Pfefferkorn and Kasper, 1983), these mutations
have not been defined. The advent of next-generation sequencing
approaches may facilitate a better understanding of this strain in
future. Other studies on live vaccines indicate that stage-specific
antigens and administration routes may play an important role
in the protective immune response against the enteric stages of
T. gondii. For example, immunisation by oral or duodenal adminis-
tration of T-263 tachyzoites failed to prevent oocyst shedding upon
subsequent challenge of cats (Freyre et al., 1993). Similarly, immu-
nisation of cats by the intramuscular injection of 60Co-irradiated
tachyzoites of the Beverley strain prevented oocyst shedding in
only 43% of the immunised cats following challenge with homolo-
gous bradyzoites, and immunisation with 60Co-irradiated tachy-110zoites of the RH strain failed to prevent oocyst shedding upon
challenge with bradyzoites of the heterologous Beverley strain
(Omata et al., 1996). Recently, the aforementioned MIC1-3KO
strain was investigated as a live attenuated vaccine for cats.
Although promising results were reported in mice and sheep,
immunisation of cats with tachyzoites of the MIC1-3KO strain by
either the subcutaneous or oral route did not protect against oocyst
shedding (Le Roux et al., 2020).
There is reason to hope that targeted attenuated vaccines are a
realistic proposition. RNA-sequencing data and analyses of cat
enteric stages of T. gondii (Behnke et al., 2014; Hehl et al.,
2015; Ramakrishnan et al., 2019) have provided valuable insights
into genes expressed specifically in merozoites, microgametes
and macrogametes with presumptive roles in sexual reproduction
and oocyst formation. These studies bring with them the opportu-
nity to design vaccines that specifically target the feline enteric
stages of T. gondii. Indeed, to establish proof-of-principle, a
CRISPR/Cas9 gene-editing strategy was used to engineer a T. gon-
dii strain lacking the expression of a putative microgamete-
specific fertilisation factor, HAP2 (Ramakrishnan et al., 2019).
Infection of rats with HAP2-deficient tachyzoites led to the estab-
lishment of chronic infection and tissue cyst development. Pri-
mary infection of cats with bradyzoite-containing cysts from
these rats demonstrated that HAP2-deficient T. gondii parasites
were unable to complete fertilisation and, as a result, very few
oocysts were produced and those that were had an aberrant mor-
phology and could not undergo meiosis to form infectious sporo-
zoites within oocysts. Moreover, all cats previously immunised by
infection with the HAP2-deficient T. gondii parasites shed no
oocysts upon challenge with bradyzoite-containing cysts from
the wild-type parental strain (Ramakrishnan et al., 2019). An
impediment to application of a targeted attenuated vaccine to
block transmission of T. gondii oocysts is, as it was for the T-
263 mutant strain, the provision of bradyzoites for immunising
infection of kittens. However, the recent identification of a master
switch for the conversion of tachyzoites to bradyzoites (Waldman
et al., 2020) significantly improves the prospects for development
of an in vitro ‘‘cell factory” system for the mass production of
bradyzoites.6. Nanotechnology for the control of toxoplasmosis
The use of nanomaterials in medicine has been termed nano-
medicine (Soares et al., 2018) and, increasingly, nanoparticles
are being assessed for inclusion in a range of diagnostic, thera-
peutic and preventative applications. Nanomaterials can be
defined as organic or inorganic, crystalline or amorphous particles
in the range of tens to hundreds of nanometres in size (Assolini
et al., 2017; Soares et al., 2018). They can be organised as single
particles, aggregates, powders, or dispersed in a matrix to form
suspensions, emulsions or nanolayer films (Soares et al., 2018).
A consequence of their size is a very large surface area to volume
ratio, making them much more reactive than larger particles. This
gives them a tendency to adsorb biomolecules when in contact
with biological fluids so that a layer known as the corona forms
on the surface of colloidal nanoparticles. Their size also allows
them to penetrate cells and interact with intracellular molecules.
Their biological interactions are also influenced by shape, chemi-
cal composition, surface charge and roughness, allowing them to
be tailor-made for specific targets (Soares et al., 2018). Their
diversity makes them very versatile and nanoparticles have been
used to improve diagnostic assays, as a new way of delivering
chemotherapy or vaccine formulations, or as therapeutic agents
and adjuvants themselves.
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Diagnosis of acute infections with T. gondii is usually through
the detection of anti-T. gondii IgM, IgA, IgE or IgG antibodies in
the serum of patients by ELISA, indirect haemagglutination tests
or immunosorbent agglutination tests (Ybañez et al., 2020). An
increase in IgM, IgA and IgE is considered to be characteristic of
an acute infection, whereas detection of only IgG is characteristic
of a chronic or previous infection (Ybañez et al., 2020). A major
drawback to these methods is low sensitivity, which results in
false negatives. Accurate diagnosis can also be complicated by
the presence of immunosuppressed patients who produce very
low levels of IgM or patients who can produce IgM for up to a
year after initial infection (Ybañez et al., 2020). A number of stud-
ies have aimed to increase the sensitivity of the assays by the
inclusion of nanoparticles due to increased surface area available
for adsorption of reagents (Medawar-Aguilar et al., 2019). Assays
that have been developed include a microfluidic assay using zinc
oxide nanoparticles coated with chitosan (Medawar-Aguilar et al.,
2019) and an electrochemical immunosensor consisting of gra-
phene sheets, goldmag (Au-Fe3O4) nanoparticles and thionine
(Jiang et al., 2013). Both of these assays used T. gondii lysate con-
jugated to the nanoparticles to capture anti-T. gondii antibodies in
serum samples and demonstrated increased sensitivity compared
with conventional sandwich ELISAs. Li et al. (2015) used goldmag
nanoparticles modified with polymethacrylic acid conjugated
with anti-human IgM antibodies in a lateral flow immunochro-
matographic assay (LFIA) to test for the TORCH pathogens (Toxo-
plasma, rubella virus, cytomegalovirus and herpes simplex virus)
in pregnant women (Li et al., 2015). This assay also displayed
increased sensitivity and specificity compared with commercially
available LFIA assays. TORCH pathogens were also targeted in the
development of a microarray using quantum dots (photolumines-
cent nanomaterials) coated with antigens to detect infections in
serological samples (Yang et al., 2009). This assay had comparable
sensitivity and specificity to conventional ELISA but had the
advantage of a shorter run time and a more stable signal (Yang
et al., 2009).
Toxoplasmosis can also be diagnosed through direct detection
of T. gondii. This is particularly useful in immunocompromised
patients where a serological response is reduced and there is the
risk of false negative results. These tests can be developed to detect
either DNA or antigens of the parasite. As with assays to detect
antibodies, nanoparticles were used to increase the sensitivity of
diagnostic assays that detect parasite antigen. Aly et al. (2018)
used silica particles coated with polyclonal antibodies to T. gondii
lysate to detect circulating parasite antigen in serological and urine
samples. Sensitivity was increased from 85.7% to 90% for serum
samples and 78.6% to 82.6% in urine samples (Aly et al., 2018).
Hegazy et al. (2015) used immunomagnetic beads coated with
antibodies to SAG1 to detect parasite antigens in serological sam-
ples, increasing sensitivity from 92% to 98%. Xu et al. (2013) devel-
oped a probe using nickel-magnetic nanoparticles and fluorescence
resonance energy transfer to detect T. gondii DNA, although it
should be noted that the probe was not validated using patient
samples. It is unlikely that sensitivity of this probe would exceed
that of the real-time PCR assay developed by Lin et al. (2000), lim-
iting its usefulness.
In addition to increased sensitivity and specificity of diagnostic
tests incorporating nanoparticles, the speed, cost and convenience
were also often improved compared with existing tests. These
improvements have led to a more accurate diagnosis and faster
implementation of appropriate treatments for patients identified
as suffering from toxoplasmosis.1116.2. Nanotechnology in the treatment of T. gondii infection
As discussed above, the most commonly used drugs for human
toxoplasmosis are sulfadiazine and pyrimethamine, both of which
can cause serious side effects such as bone marrow suppression,
allergy and renal and hepatic complications (Gaafar et al., 2014).
Other drugs, including a range of antibiotics and anti-malarials,
have also been used but they can also have serious side effects
(Abou-El-Naga et al., 2017). The unique physicochemical proper-
ties of nanoparticles can be harnessed to improve delivery of drugs
by altering their pharmacokinetics. This can lead to a slower drug
delivery, better target specificity, increased efficacy and a reduc-
tion in side effects (Anand et al., 2015). Drugs that are toxic, or
have poor solubility, or are easily degraded in the gastrointestinal
tract, can be delivered into the body for more effective treatment at
lower doses using nanotechnology-based approaches. Nanoparti-
cles have been evaluated both as a way of delivering current
anti-toxoplasmosis treatments more effectively and as anti-
microbial agents themselves (Pissuwan et al., 2009).
Chitosan is a natural polysaccharide that has been shown to
have anti-bacterial and anti-malarial effects, and has been investi-
gated for anti-Toxoplasma effects (Teimouri et al., 2018). Low
molecular weight (86 kDa), medium molecular weight (234 kDa)
and high molecular weight (353 kDa) nanoparticles were synthe-
sised and tested against RH strain T. gondii in vitro and in vivo.
Anti-T. gondii activity was demonstrated in vitro with all nanopar-
ticle sizes but killing of exposed tachyzoites was fastest with low
molecular weight nanoparticles. Smaller nanoparticles also per-
formed best in an in vivo model, resulting in a significant drop in
parasite burden compared with infected, untreated mice; however,
they were not as effective as treatment with sulfadiazine (Teimouri
et al., 2018). Addition of anti-T. gondii drugs to chitosan nanoparti-
cles did, however, increase effectiveness of parasite killing com-
pared with chitosan or the drug alone. Spiramycin is an
antibiotic that is used to treat toxoplasmosis in pregnant women
but is limited in its effectiveness by low bioavailability and an
inability to cross the blood–brain barrier. Loading of spiramycin
into chitosan nanoparticles increased its absorption and perme-
ation, increasing survival time and reducing parasite burden in
mice compared with spiramycin or chitosan nanoparticles alone.
The inflammatory response to infection was lessened in the treated
animals and the parasites that were isolated showed morphologi-
cal deformities, indicating a direct effect of the spiramycin-
chitosan nanoparticles on the parasites themselves (Etewa et al.,
2018; Hagras et al., 2019). Similarly, Abou-El-Naga et al. (2017)
found that administration of the anti-retroviral lopinvar/ritonavir
combination encapsulated in polylactic-co-glycolic acid (PLGA)
nanoparticles to mice infected with T. gondii reduced parasite bur-
den significantly compared with administration as free drug. Infec-
tivity of tachyzoites exposed to lopinvar/ritonavir in PLGA
nanoparticles was also reduced significantly compared with tachy-
zoites frommice treated with free drug, although mortality rates in
the two groups were not significantly different (Abou-El-Naga
et al., 2017).
Mixed results have been seen with other potential anti-Toxo-
plasma drugs loaded into nanoparticles, with effects seemingly
dependent on the pharmacokinetics of individual drugs. Triclosan,
an inhibitor of fatty acid synthesis, is a drug with promising activ-
ity against protozoan parasites in vitro, but its poor solubility has
limited its use in vivo. Loading triclosan into nanoparticles
comprised of lipids (liposomes) significantly reduced parasite
burden in mice infected with a virulent strain of T. gondii compared
with triclosan alone (El-Zawawy et al., 2015a). Surprisingly, similar
experiments using an avirulent strain of T. gondii found no
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somes compared with triclosan alone, although both groups had
significant reductions in parasite burden compared with infected,
untreated mice (El-Zawawy et al., 2015b). This may indicate a T.
gondii strain effect on the mode of action of the drug, although dif-
ferent doses of triclosan and triclosan/liposomes were used in the
studies, complicating comparisons. Bottari et al., (2015) compared
brain cyst burdens in mice infected with T. gondii then treated with
sulfamethoxazole/trimethoprim and reseveratrol packaged into
nanoparticles or as free drug. They found a significant reduction
in cyst burden in mice treated with sulfamethoxazole/trimetho-
prim and resveratrol compared with mice treated with sul-
famethoxazole/trimethoprim only, but there was no significant
difference between the two delivery methods of reseveratrol
(Bottari et al., 2015).
Chitosan nanoparticles have also been combined with silver
nanoparticles to increase their efficacy (Gaafar et al., 2014). Mice
infected with T. gondii were treated with pyrimethamine, chitosan
nanoparticles, silver nanoparticles, or a combination of chitosan
and silver nanoparticles. Parasite burden was significantly reduced
after treatment with silver nanoparticles or the combination of sil-
ver and chitosan nanoparticles, pyrimethamine or chitosan parti-
cles. However, there was no significant difference between silver
nanoparticles and the combination of silver and chitosan nanopar-
ticles, suggesting it is the silver nanoparticles that had the anti-T.
gondii effect (Gaafar et al., 2014). This finding is supported by
in vitro studies with gold, silver and platinum nanoparticles by
Adeyemi et al. (2017) who found tachyzoite viability was reduced
by 90% in the presence of the metallic nanoparticles. The selectivity
index was 20, indicating marked toxicity towards the parasite
without affecting the host cells. Silver and gold nanoparticles were
more effective than platinum at killing the parasites (Adeyemi
et al., 2017). In a subsequent study, T. gondii parasites exposed to
metallic nanoparticles were impaired in converting from tachy-
zoite to bradyzoite in vitro (Adeyemi et al., 2019), suggesting that
metallic nanoparticles target both tachyzoites and bradyzoites.
Killing of parasites was linked to the production of reactive oxygen
species stimulated by the metal nanoparticles (Adeyemi et al.,
2017, 2019). A further study using combinations of the metals con-
firmed their anti-T. gondii activity but noted some potential safety
concerns since the selectivity index of effect on parasite versus
host cells was  2-fold (Adeyemi et al., 2018b).
Recently, plant extracts have been used as stabilising or reduc-
ing agents in the preparation of so-called ‘‘biogenic” nanoparticles.
This manufacturing method has the advantages of being more cost
effective, producing less toxic waste, and generating more reactive
nanoparticles. Coating the particles with plant molecules also
increases their biocompatibility (Sharma et al., 2019). Alajmi
et al. (2019) used extracts of date seeds and nabka leaves to pro-
duce biogenic silver nanoparticles and examined their effect on
survival rate and hepatic damage in mice infected with T. gondii.
Mice treated with the biogenic nanoparticles or sulfadiazine sur-
vived for longer than infected, untreated mice. Mice given the bio-
genic silver particles showed less signs of hepatic damage due to
the infection but the mortality rate was higher than in mice given
sulfadiazine (Alajmi et al., 2019). This treatment may have been
more effective if a less virulent strain of T. gondii had been used
for the experiments. Machado et al. (2020) created biogenic silver
nanoparticles with the fungus, Fusarium oxysporum, and assessed
their effect on T. gondii in vitro. Treatment with the nanoparticles
significantly reduced the ability of parasites to invade and prolifer-
ate inside HeLa cells (Machado et al., 2020). These results were
consistent with those obtained by Gaafar et al. (2014) and
Adeyemi et al. (2017), although how the silver nanoparticles are
damaging the parasite remains to be determined. Biogenic sele-
nium nanoparticles created with Bacillus were also found to be112effective against T. gondii in chronically infected mice (Keyhani
et al., 2020). A significant reduction in brain cysts was seen in
chronically infected mice treated for 14 days with the selenium
nanoparticles compared with untreated mice, although complete
elimination was not achieved. No toxicity was observed in the mice
although mRNA levels of inflammatory cytokines were raised, and
the authors speculated that the reason for the decrease in brain
cysts was due to induction of an inflammatory response by sele-
nium (Keyhani et al., 2020). Another study by the same group
showed that biogenic selenium nanoparticles administered prior
to infection could significantly reduce parasite burden in a model
of acute toxoplasmosis (Shakibaie et al., 2020).
Toxicity can be an issue with metal nanoparticles as they are
not biodegradable like other types, such as chitosan or liposomes,
and can accumulate in organs. However, the nanoparticles tested
to date display toxicity towards the parasite and, apart from one
study (Adeyemi et al., 2018b), show little toxicity towards host
cells in vitro or in vivo. The alterations that packaging drugs in
nanoparticles makes to the pharmacokinetics of those drugs may
lead to lower doses being effective. This, in turn, gives hope that
this approach will lead to more effective treatments with fewer
side effects for patients. However, it does need to be acknowledged
that nanoparticles can compromise pregnancy (Park et al., 2013;
Elsharawy et al., 2020) and this will potentially limit their utility
in control of congenital toxoplasmosis.
6.3. Nanotechnology in vaccines against T. gondii infection
Immunogenicity is an issue with subunit and DNA vaccines. The
plasmids and antigens that make up these vaccines are prone to
enzymatic degradation and can be poorly taken up by the relevant
cells so that only a weak immune response is stimulated (Maeta
et al., 2020). Nanoparticles can act as adjuvants and have been
shown to increase immunogenicity of a number of T. gondii anti-
gens that have potential as vaccine candidates including ROP18
(Nabi et al., 2017) and SAG1 (Naeem et al., 2018). Peptides corre-
sponding to epitopes of key antigens (SAG1, AMA1, ROP2 and
GRA4) have been encapsulated in nanoparticles and tested for
immunogenicity (Roozbehani et al., 2018). Unlike commonly used
adjuvants, such as alum, nanoparticles appear able to induce cellu-
lar and humoral responses that are more likely to produce a pro-
tective response. Another benefit of encapsulating subunit
vaccines in nanoparticles is that encapsulation can guard against
degradation. In addition to this, nanoparticles can be targeted for
delivery to certain cells by the adsorption of antibodies on their
surfaces, and lower amounts of DNA and protein can be used in
the formulation, reducing the risk of toxicity and side effects
(Wang et al., 2019).
The properties of nanoparticles allow efficient delivery of vac-
cine candidates via routes other than subcutaneous or intramuscu-
lar. Dimier-Poisson et al. (2015) used nasal delivery to immunise
mice with a total extract T. gondii antigens loaded onto nanoparti-
cles made of maltodextrin and challenged mice with lethal and
chronic doses of T. gondii. All mice immunised with the antigen/-
nanoparticle combination survived a lethal challenge infection
and had reduced cyst burdens in the chronic model compared with
mice immunised with antigen alone. Ducournau et al. (2017) found
the same formulation could also reduce vertical transmission in
immunised mice infected during pregnancy.
DNA vaccines can stimulate a cellular response that is most
effective for intracellular pathogens (Maeta et al., 2020) and
nanoparticles have been shown to increase their effectiveness.
Issues affecting the success of DNA vaccines include degradation
of the DNA by extracellular nucleases, poor uptake by cells, and
inability to escape the endosome once inside the cell (Maeta
et al., 2020). Nanoparticles protect DNA from degradation during
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calcium phosphate nanoparticles to DNA vaccine formulations
based on GRA14 and ROM4 have been shown to increase their
immunogenicity in mice and prolong survival against a challenge
with T. gondii RH (Ahmadpour et al., 2017; Rahimi et al., 2017;
Pagheh et al., 2019). Maeta et al. (2020) were also able to demon-
strate significant protection against T. gondii in mice immunised
with DNA encoding T. gondii profilin encapsulated in liposomal
nanocarriers.
A risk with DNA vaccines is their potential integration into the
host genome. To overcome this possibility, a modified dendrimer
nanoparticle that encapsulated RNA encoding for six T. gondii anti-
gens (GRA6, ROP2A, ROP18, SAG1, SAG2A and AMA1) was devel-
oped. This vaccine was able to stimulate a cellular adaptive
immune response and protect mice against a lethal challenge with
T. gondii (Chahal et al., 2016). Luo et al. (2017) also encased RNA
coding for T. gondii NTPase II in synthetic lipid nanoparticles and
found a significantly increased cellular and humoral response in
mice immunised with the RNA in lipid nanoparticles compared
with the RNA alone. Mice immunised with the nanoparticles had
prolonged survival rates when challenged with T. gondii RH
although there was no significant advantage conferred by the
nanoparticles when mice were challenged with T. gondii Pru. Cyst
burden was reduced compared with untreated, infected mice but
was not significantly different from mice immunised with only
the RNA (Luo et al., 2017).
As was noted for diagnostic tests and administration of thera-
peutic drugs, nanoparticles have the potential to increase the effec-
tiveness of vaccine formulations and, therefore, should be
considered for inclusion in any development of vaccines to target
toxoplasmosis.7. Concluding remarks
Toxoplasma gondii has been described, with justification, as ‘‘the
world’s most successful parasite” and ‘‘the model apicomplexan”
(Weiss and Kim, 2020). It is a parasite that can seemingly infect
any nucleated cell in any warm-blooded animal, has spread across
the Earth from origins in South America, adapting to human agri-
cultural development in the process, and causes only minor, if
any, symptoms in the majority of its hosts. However, the sheer
enormity of the numbers of people and animals infected with this
parasite make it one of the most globally significant zoonotic dis-
eases. On health, economic and ecological grounds, the control of
toxoplasmosis is therefore a necessity, not a luxury.
The success of T. gondii is underpinned by an exquisitely com-
plex life cycle, which means that the manifestations of toxoplas-
mosis are also complex. Public education is, therefore, critically
important, notwithstanding doubts about its effectiveness. It is
particularly important for pregnant women and immunocompro-
mised people but it must be clever, informative, detailed and prac-
tical enough to enable clear communication between medical
professionals and their patients, and to encourage adherence to
measures and habits that will reduce exposure to oocysts and cysts
of T. gondii for those most at risk. Additionally, freely available
accurate and practical information about toxoplasmosis is useful
for both medical professionals and the general public. There is
some evidence that this can have an effect since education is con-
sidered at least partly responsible for an apparent reduction, over
recent decades, in prevalence of infection with T. gondii in, e.g.,
the U.S.A. (Jones et al., 2007, 2014), the Netherlands (Hofhuis
et al., 2011), France (Nogareda et al., 2014) and Germany
(Wilking et al., 2016), particularly through improved understand-
ing of food and water hygiene.113Protection of food and water from contamination with T. gondii
is a requisite for control of human toxoplasmosis. Biosecurity mea-
sures to minimise the presence of cats and rodents on farms is
important, particularly since post-harvest detection and removal
of the parasite in or on food is not straightforward. Availability of
water that is oocyst-free is absolutely essential, not just for human
consumption but also for raising livestock and producing crops. By
2020, access to clean water should be a right, not a privilege but,
sadly, this is not the case and it is no coincidence that the signifi-
cant incidence of toxoplasmosis traceable to oocyst-derived infec-
tion is often linked to socio-economic status (Bahia-Oliveira et al.,
2003; Carellos et al., 2014; Singh et al., 2014; Mareze et al., 2019;
Shapiro et al., 2019). Thus, a genuine global effort to address pov-
erty and ensure provision of clean water for all people would go a
long way to reducing the incidence of toxoplasmosis.
Timely treatment following diagnosis of infection with T. gondii
is important, particularly for pregnant women and immunosup-
pressed people – it saves lives even if current drugs do not possess
all the characteristics and efficacy of the ideal therapy. The pro-
spects for new, better targeted drugs are real, fueled by insights
into the parasite’s genome, transcriptome and biochemistry. Addi-
tionally, nanotechnological advances have the potential to improve
delivery of existing and future chemotherapeutic agents. Similarly,
new insights into the immunobiology of toxoplasmosis are paving
the way for the development of immunotherapeutics, particularly
to prevent toxoplasmic encephalitis resulting from
immunosuppression.
Live attenuated vaccines have proven to be effective in both
intermediate and definitive hosts of T. gondii but subunit vaccines
have not. This probably tells us something about the importance of
cell-mediated immunity in both intermediate and definitive hosts
(Innes et al., 2019), and perhaps also exposes our current lack of
understanding and options for antigen presentation in the delivery
of subunit vaccines; nanotechnology may help address this. In the
meantime, recent research has utilised the availability of robust
data sets for the genome and transcriptomes of T. gondii, combined
with the gene editing power of CRISPR/Cas9 protocols to demon-
strate that: (i) single transcription factors largely control the
switch to sexual stage development (Farhat et al., 2020) and brady-
zoite development (Waldman et al., 2020) in T. gondii; and (ii) kit-
tens can be rendered totally incapable of transmitting viable
oocysts following immunisation with a parasite strain gene-
edited to prevent expression of a parasite fertilisation factor
(Ramakrishnan et al., 2019). The discovery of a master-regulator
of conversion of tachyzoites to bradyzoites opens the door to
development of an attenuated vaccine for intermediate hosts that
will have an inbuilt safeguard of not being able to progress into a
long-lived tissue cyst. This is particularly attractive since cultiva-
tion of tachyzoites in vitro is not difficult and may well be amen-
able to commercial scale-up. This same discovery also paves the
way for potential scale-up of in vitro production of bradyzoites,
which would enable two things: first, the development of high-
throughput approaches for the discovery and testing of drugs to
treat chronic infection with T. gondii, treatments for which we lack
currently; and second, an in vitro mass production system for
bradyzoites, which could overcome one of the main obstacles to
the implementation of a transmission-blocking vaccine program
for cats using attenuated parasites. A vaccine to stop transmission
of oocysts of T. gondii is attractive because it targets the core of the
life cycle of T. gondii – without sexual reproduction and oocysts, all
routes of infection with this parasite ultimately cease to exist.
Completely preventing transmission of oocysts worldwide is,
seemingly, impossible as vaccine coverage of all pet, community,
stray and wild cats is a challenge that would necessitate delivery
technologies and regimens we have not yet imagined. But, similar
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worth our effort.
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